var title_f42_51_43824="Bence Jones protein immunofix";
var content_f42_51_43824=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F75044&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F75044&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Urinary monoclonal protein",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 341px; height: 166px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Immunofixation of a concentrated urine specimen from the previous patient with antisera to kappa and lambda light chains shows a discrete lambda band, indicating a monoclonal lambda light chain (ie, Bence Jones protein of lambda specificity).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_51_43824=[""].join("\n");
var outline_f42_51_43824=null;
var title_f42_51_43825="Congenital gen lipodystrophy";
var content_f42_51_43825=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F78980&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F78980&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 522px\">",
"   <div class=\"ttl\">",
"    Patients with congenital generalized lipodystrophies",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 502px; height: 603px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This panel shows a woman and a man with congenital generalized lipodystrophy types 1 and 2. Type 1 is due to a mutation in the 1-acylglycerol-3-phosphate O-acyltransferase 2 gene. Type 2 is due to a mutation in the seipin gene. Both types are characterized by a generalized lack of fat, extreme muscularity, acanthosis nigricans in the groin and axillae, and acromegaloid features. Patients with CGL2 have a higher prevalence of intellectual impairment and cardiomyopathy than those with CGL1.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_51_43825=[""].join("\n");
var outline_f42_51_43825=null;
var title_f42_51_43826="Tolnaftate: Pediatric drug information";
var content_f42_51_43826=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"8\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Tolnaftate: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?27/61/28627?source=see_link\">",
"    see \"Tolnaftate: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?38/62/39907?source=see_link\">",
"    see \"Tolnaftate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F229126\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Blis-To-Sol&reg; [OTC];",
"     </li>",
"     <li>",
"      Mycocide&reg; NS [OTC];",
"     </li>",
"     <li>",
"      Podactin Powder [OTC];",
"     </li>",
"     <li>",
"      Tinactin&reg; Antifungal Deodorant [OTC];",
"     </li>",
"     <li>",
"      Tinactin&reg; Antifungal Jock Itch [OTC];",
"     </li>",
"     <li>",
"      Tinactin&reg; Antifungal [OTC];",
"     </li>",
"     <li>",
"      Tinaderm [OTC];",
"     </li>",
"     <li>",
"      Ting&reg; Cream [OTC];",
"     </li>",
"     <li>",
"      Ting&reg; Spray Liquid [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F229127\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Pitrex",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1050377\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antifungal Agent, Topical",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1050372\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?27/61/28627?source=see_link\">",
"      see \"Tolnaftate: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children and Adults: Topical: Spray aerosol or apply 1-3 drops of solution or a small amount of cream or powder and rub into the affected areas 2-3 times/day for 2-4 weeks",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F229118\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aerosol, powder, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tinactin&reg; Antifungal: 1% (133 g) [contains ethanol 11% v/v, talc]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tinactin&reg; Antifungal Deodorant: 1% (133 g) [contains ethanol 11% v/v, talc]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tinactin&reg; Antifungal Jock Itch: 1% (133 g) [contains ethanol 11% v/v, talc]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aerosol, spray, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tinactin&reg; Antifungal: 1% (150 g) [contains ethanol 29% v/v]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ting&reg; Spray Liquid: 1% (128 g) [contains ethanol 41% w/w]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical: 1% (15 g, 30 g, 114 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tinactin&reg; Antifungal: 1% (15 g, 30 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tinactin&reg; Antifungal Jock Itch: 1% (15 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ting&reg; Cream: 1% (15 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Blis-To-Sol&reg;: 1% (30 mL, 55 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, topical [spray]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tinactin&reg; Antifungal: 1% (59 mL) [contains ethanol 70% v/v]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder, topical: 1% (45 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Podactin Powder: 1% (60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tinactin&reg; Antifungal: 1% (108 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mycocide&reg; NS: 1% (30 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tinaderm: 1% (10 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F229106\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Cream, powder, solution",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1050380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical: Wash and dry affected area before drug application; avoid contact with eyes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1050379\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of tinea pedis, tinea cruris, tinea corporis, tinea manuum caused by",
"     <i>",
"      Trichophyton rubrum",
"     </i>",
"     ,",
"     <i>",
"      T. mentagrophytes",
"     </i>",
"     ,",
"     <i>",
"      T. tonsurans",
"     </i>",
"     ,",
"     <i>",
"      M. canis",
"     </i>",
"     ,",
"     <i>",
"      M. audouinii",
"     </i>",
"     , and",
"     <i>",
"      E. floccosum",
"     </i>",
"     ; also effective in the treatment of tinea versicolor infections due to",
"     <i>",
"      Malassezia furfur",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F229161\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Tinactin&reg; may be confused with Talacen",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F229160\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Contact dermatitis, pruritus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Irritation, stinging",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1050383\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to tolnaftate or any component; nail and scalp infections",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300155\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F229114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1050376\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Resolution of skin infection",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1050371\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Distorts the hyphae and stunts mycelial growth in susceptible fungi",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1050382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Onset of action: Response may be seen 24-72 hours after initiation of therapy",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1050375\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?38/62/39907?source=see_link\">",
"      see \"Tolnaftate: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid contact with the eyes; apply to clean dry area; consult the physician if a skin irritation develops or if the skin infection worsens or does not improve after 10 days of therapy",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1050384\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Usually not effective alone for the treatment of infections involving hair follicles or nails",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12849 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-61.234.146.186-8377BC303A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_51_43826=[""].join("\n");
var outline_f42_51_43826=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229126\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229127\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050377\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050372\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229118\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229106\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050380\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050379\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229161\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229160\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050383\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300155\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229114\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050376\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050371\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050382\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050375\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050384\">",
"      Additional Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12849\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12849|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?27/61/28627?source=related_link\">",
"      Tolnaftate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?38/62/39907?source=related_link\">",
"      Tolnaftate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_51_43827="Ketorolac (ophthalmic): Pediatric drug information";
var content_f42_51_43827=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ketorolac (ophthalmic): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?34/32/35332?source=see_link\">",
"    see \"Ketorolac (ophthalmic): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?19/0/19460?source=see_link\">",
"    see \"Ketorolac (ophthalmic): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8346944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Acular LS&reg;;",
"     </li>",
"     <li>",
"      Acular&reg;;",
"     </li>",
"     <li>",
"      Acuvail&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8346945\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Acular LS&reg;;",
"     </li>",
"     <li>",
"      Acular&reg;;",
"     </li>",
"     <li>",
"      Apo-Ketorolac&reg; Ophthalmic;",
"     </li>",
"     <li>",
"      ratio-Ketorolac",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10501736\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anti-inflammatory Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Nonsteroidal Anti-inflammatory Drug (NSAID), Ophthalmic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10503727\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?34/32/35332?source=see_link\">",
"      see \"Ketorolac (ophthalmic): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Children and Adolescents:",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;\">",
"     <b>",
"      Seasonal allergic conjunctivitis:",
"     </b>",
"     Acular&reg;: Children &ge;3 years, Adolescents: Ophthalmic: Instill 1 drop in eye(s) 4 times daily",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;\">",
"     <b>",
"      Postoperative inflammation:",
"     </b>",
"     Acular&reg;: Children &ge;3 years, Adolescents: Ophthalmic: Instill 1 drop in affected eye(s) 4 times daily starting 24 hours after cataract surgery and through 14 days after surgery",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;\">",
"     <b>",
"      Postoperative pain, burning, and stinging:",
"     </b>",
"     Acular LS&trade;: Children &ge;3 years, Adolescents: Ophthalmic: Instill 1 drop in affected eye 4 times daily as needed for up to 4 days after corneal refractive surgery",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;\">",
"     <b>",
"      Seasonal allergic conjunctivitis (relief of ocular itching):",
"     </b>",
"     Acular&reg;: Ophthalmic: Instill 1 drop 4 times daily",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;\">",
"     <b>",
"      Inflammation following cataract extraction:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:4em;\">",
"     Acular&reg;: Ophthalmic: Instill 1 drop to affected eye(s) 4 times daily beginning 24 hours after surgery; continue for 2 weeks",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:4em;\">",
"     Acuvail&reg;: Ophthalmic: Instill 1 drop twice daily into affected eye; begin treatment 1 day prior to cataract surgery and continue on day of surgery, and for 2 weeks postoperatively",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;\">",
"     <b>",
"      Pain following corneal refractive surgery:",
"     </b>",
"     Acular LS&reg;: Ophthalmic: Instill 1 drop 4 times daily as needed to affected eye for up to 4 days",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8353219\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic, as tromethamine [drops]: 0.4% (5 mL); 0.5% (3 mL, 5 mL, 10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Acular LS&reg;: 0.4% (5 mL) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Acular&reg;: 0.5% (5 mL) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic, as tromethamine [drops, preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Acuvail&reg;: 0.45% (0.4 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8346947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10503726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May contain benzalkonium chloride which may be absorbed by contact lenses; contact lenses should not be worn during treatment. Instill drops into affected eye(s); avoid contact of container tip with skin or eyes; apply finger pressure to lacrimal sac during and for 1-2 minutes after instillation to decrease risk of absorption and systemic effects; wait at least 5 minutes before administering other ophthalmic drops. To minimize the risk of infection following surgery of both eyes, two separate bottles of eye drops (one for each eye) should be used; instruct patients not to use the same bottle for both eyes.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F10503724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acular&reg;, Acular LS&reg;: Store at 15&deg;C to 25&deg;C (59&deg;F to 77&deg;F); protect from light.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acuvail&reg;: Store at 15&deg;C to 30&deg;C (59&deg;F to 86&deg; F) in pouch with pouch ends folded closed; protect from light; single use vials, discard after use.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10503706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acular&reg;: Treatment of ocular itch associated with seasonal allergic conjunctivitis; postoperative pain and/or inflammation following cataract extraction (FDA approved in ages &ge;3 years and adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acular LS&trade;: Reduction of ocular pain, burning, and stinging after corneal refractive surgery (FDA approved in ages &ge;3 years and adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acuvail&reg;: Treatment of postoperative pain and inflammation following cataract surgery (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8320260\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Acular&reg; may be confused with Acthar&reg;, Ocular",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Ketorolac may be confused with Ketalar&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F8347264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Conjunctival hyperemia, corneal infiltrates, iritis, ocular edema, ocular inflammation, ocular irritation, ocular pain, superficial keratitis, superficial ocular infection, transient burning/stinging",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reactions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Corneal erosion, corneal perforation, corneal thinning, corneal ulcer, dry eyes, epithelial breakdown",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10501737\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ketorolac or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10503707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with complicated ocular surgeries, corneal denervation, epithelial defects, diabetes, rheumatoid arthritis, ocular surface diseases (eg, dry eye syndrome) or ocular surgeries repeated within short periods of time; corneal thinning, erosion, or ulceration leading to possible loss of vision have been reported; discontinue if corneal epithelial breakdown occurs. Use for &gt;24 hours prior to or for &gt;14 days following surgery also increases risk of corneal adverse effects. Use with caution in patients with known bleeding tendencies or those receiving anticoagulants; may increase bleeding time associated with ocular surgery.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use with caution in patients with sensitivity to acetylsalicylic acid, phenylacetic acid derivatives, or other nonsteroidal anti-inflammatory agents; bronchospasm or exacerbation of asthma may occur.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     May contain benzalkonium chloride which may be absorbed by contact lenses; contact lenses should not be worn during treatment. Allow at least 5 minutes between applications with other eye drops. To avoid contamination, do not touch tip of container to any surface. To minimize the risk of infection following surgery of both eyes, two separate bottles of eye drops (one for each eye) should be used; instruct patients not to use the same bottle for both eyes.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299557\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8349375\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Latanoprost: NSAID (Ophthalmic) may diminish the therapeutic effect of Latanoprost.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8346949\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8346950\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in animal studies; therefore, the manufacturer classifies ketorolac ophthalmic as pregnancy category C. When administered I.M., ketorolac crosses the placenta. Refer to the Ketorolac (Systemic) monograph for details. The amount of ketorolac available systemically following topical application of the ophthalmic drops is significantly less in comparison to oral doses. Because they may cause premature closure of the ductus arteriosus, the use of NSAIDs late in pregnancy (including ketorolac ophthalmic drops) should be avoided.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10503725\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits prostaglandin synthesis by decreasing the activity of the enzyme, cyclooxygenase, which results in decreased formation of prostaglandin precursors",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F10501738\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?19/0/19460?source=see_link\">",
"      see \"Ketorolac (ophthalmic): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Wash hands before instilling. Sit or lie down to instill. Do not let tip of applicator touch eye; do not contaminate tip of applicator (may cause eye infection, eye damage, or vision loss). Temporary stinging or blurred vision may occur. Do not wear soft contact lenses. Report persistent pain, burning, double vision, swelling, itching, or worsening of condition. If other ophthalmic drops prescribed, wait at least 5 minutes before administering other eye drops. To minimize the risk of infection following surgery of both eyes, two separate bottles of eye drops (one for each eye) should be used; instruct patients not to use the same bottle for both eyes.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16006 Version 24.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-190.81.197.98-E0CB579620-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_51_43827=[""].join("\n");
var outline_f42_51_43827=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8346944\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8346945\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10501736\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503727\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8353219\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8346947\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503726\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503724\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503706\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8320260\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8347264\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10501737\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503707\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299557\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8349375\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8346949\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8346950\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503725\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10501738\">",
"      Patient Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16006\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16006|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?4/48/4872?source=related_link\">",
"      Ketorolac (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?40/59/41909?source=related_link\">",
"      Ketorolac (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?34/32/35332?source=related_link\">",
"      Ketorolac (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?19/0/19460?source=related_link\">",
"      Ketorolac (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?21/1/21529?source=related_link\">",
"      Ketorolac (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?3/33/3606?source=related_link\">",
"      Ketorolac (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/22/1385?source=related_link\">",
"      Ketorolac (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_51_43828="X-ray shear fracture T12";
var content_f42_51_43828=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F83508&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F83508&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    X-ray shear fracture T12",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 314px; height: 656px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The plain x-ray of the thoracolumbar spine in AP (A and B) and lateral projections (C and D) reveals a fracture dislocation centered around T11/T12. The red arrows define the spinous processes on the frontal film and demonstrate the abrupt angulation centered at the dislocated level. The yellow arrows point to the posterior cortices of the vertebral bodies and highlight the extent of abnormal translation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Richard Waite, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_51_43828=[""].join("\n");
var outline_f42_51_43828=null;
var title_f42_51_43829="Endocrine dysfunction in the nephrotic syndrome";
var content_f42_51_43829=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Endocrine dysfunction in the nephrotic syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/51/43829/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/51/43829/contributors\">",
"     Jai Radhakrishnan, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/51/43829/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/51/43829/contributors\">",
"     Richard J Glassock, MD, MACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/51/43829/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/51/43829/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/51/43829/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 24, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nephrotic syndrome is characterized by a marked increase in the glomerular permeability to macromolecules. The associated urinary losses of albumin and hormone-binding proteins are responsible for many of the metabolic derangements and endocrine abnormalities in these patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43829/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic review will emphasize the alterations in thyroid, vitamin D, and calcium metabolism. The effects on lipid metabolism are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/41/33430?source=see_link\">",
"     \"Lipid abnormalities in nephrotic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     THYROID FUNCTION TESTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyroid function tests reveal variable results in the nephrotic syndrome, primarily depending upon the level of protein losses in the urine. In addition, other factors that are frequently present in patients with the nephrotic syndrome, such as hypoalbuminemia, increased serum free fatty acid concentrations, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    administration, can also affect thyroid function tests&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43829/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/33/3608?source=see_link\">",
"     \"Laboratory assessment of thyroid function\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Relatively normal glomerular filtration rate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary losses of thyroxine (T4)-binding globulin (TBG) and other thyroid hormone-binding proteins (transthyretin and albumin) and the T4 bound to them result in a low total T4 concentrations in approximately 50 percent of nephrotic patients with a relatively normal glomerular filtration rate (GFR) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43829/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. Serum triiodothyronine (T3) concentrations may also be low due also to decreased binding. There is often a good correlation between the serum T4 and T3 and the serum albumin concentration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43829/abstract/7\">",
"     7",
"    </a>",
"    ]. Serum reverse T3 (rT3) concentrations are also low.",
"   </p>",
"   <p>",
"    Despite these changes, nephrotic patients are usually clinically euthyroid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43829/abstract/7\">",
"     7",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/33/3608?source=see_link\">",
"     \"Laboratory assessment of thyroid function\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The physiologically important serum free T4 and T3 concentrations are normal, as are serum thyrotropin (TSH) concentrations.",
"     </li>",
"     <li>",
"      The serum",
"      <span class=\"nowrap\">",
"       T3/T4",
"      </span>",
"      ratio is typically normal, suggesting no impairment in the conversion of T4 to T3 and therefore a normal rate of production of T3.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As a result, thyroid hormone replacement is not typically required in these patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43829/abstract/7\">",
"     7",
"    </a>",
"    ]. However, occasional patients with nephrotic syndrome who have limited thyroid reserve or are taking fixed doses of T4 may become hypothyroid due to loss of T4 in the urine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43829/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Congenital nephrotic syndrome is associated with hypothyroidism in view of massive urinary protein losses, and bilateral nephrectomy has led to correction of thyroid abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43829/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Renal failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;When impaired renal function complicates the nephrotic syndrome, the thyroid function test abnormalities are often more severe than when either renal failure or the nephrotic syndrome is present alone. If hypothyroidism is suspected clinically in such a patient, serum TSH should be measured. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/25/2453?source=see_link\">",
"     \"Thyroid function in chronic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/39/44663?source=see_link\">",
"     \"Thyroid function in nonthyroidal illness\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Effect of glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids, which are often given to treat the nephrotic syndrome, can cause a small reduction in TSH secretion and inhibit the peripheral conversion of T4 to T3. The net effect may be persistently low serum T3 and basal serum TSH concentrations, and a rise in serum rT3 concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43829/abstract/11\">",
"     11",
"    </a>",
"    ]. Thus, the serum free T4 concentrations may be the best marker of thyroid status. Patients with low serum free T4 concentrations probably should be treated as if they were hypothyroid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43829/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6339139\">",
"    <span class=\"h2\">",
"     Kidney disease associated with thyroid dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some causes of nephrotic syndrome are associated with autoimmune thyroid disease. Membranous nephropathy, for example, has been associated with both autoimmune thyroiditis (Hashimoto's disease) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43829/abstract/13\">",
"     13",
"    </a>",
"    ] and Grave's disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43829/abstract/14\">",
"     14",
"    </a>",
"    ]. Antithyroid antibodies have been reported in the glomerular immune deposits in Grave's disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43829/abstract/15\">",
"     15",
"    </a>",
"    ], and in this particular case, thyroidectomy was associated with disappearance of antithyroid antibodies, reduction of proteinuria (but not complete remission), and stabilization of GFR. Conversely, treatment of patients with Grave's disease with radioactive iodine has been associated with the appearance of membranous nephropathy and proliferative glomerulonephritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43829/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. The mechanisms linking diseases of the kidney and thyroid are not clear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     VITAMIN D AND CALCIUM METABOLISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nephrotic syndrome is associated with urinary loss of vitamin D-binding protein (VDBP), a 59-kDa protein that is filtered more easily by nephrotic glomeruli [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43829/abstract/18\">",
"     18",
"    </a>",
"    ]. In serum, calcidiol (25-hydroxyvitamin D), the precursor of the most active metabolite calcitriol, is primarily bound to VDBP and is therefore also excreted in the urine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43829/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/15/9462?source=see_link\">",
"     \"Metabolism of vitamin D\"",
"    </a>",
"    .) The net effect is a reduction in serum calcidiol concentrations, while those of calcitriol are normal or reduced [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43829/abstract/19,21,22\">",
"     19,21,22",
"    </a>",
"    ]. However, the physiologically important serum free calcitriol concentration is usually normal, suggesting that reduced total concentrations are due to loss of hormone bound to VDBP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43829/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The physiologic consequences of these changes in vitamin D metabolism on calcium homeostasis are uncertain. Hypocalcemia is a common finding in the nephrotic syndrome, due primarily to hypoalbuminemia-induced reduction in calcium binding to albumin. In general, the serum total calcium concentration will fall approximately 0.8",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.2",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    for every 1",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    (10",
"    <span class=\"nowrap\">",
"     g/L)",
"    </span>",
"    reduction in serum albumin concentration. A low serum total calcium concentration induced by hypoalbuminemia does not affect the physiologically important free (or ionized) calcium concentration. The measured serum calcium concentration can be corrected for the presence of hypoalbuminemia from the following equation:",
"   </p>",
"   <p>",
"    &nbsp;Corrected [Ca] &nbsp; = &nbsp; Measured total [Ca] &nbsp;+ &nbsp;0.8 &nbsp;x &nbsp;(4.5 &nbsp;- &nbsp;[alb])",
"   </p>",
"   <p>",
"    where the serum calcium and albumin concentrations are measured in units of",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    respectively. Thus, if the measured values are 7.6",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    and 2.5",
"    <span class=\"nowrap\">",
"     g/dL:",
"    </span>",
"   </p>",
"   <p>",
"    &nbsp;Corrected [Ca] &nbsp; = &nbsp; 7.6 &nbsp;+ &nbsp;0.8 &nbsp;x &nbsp;2 &nbsp; = &nbsp; 9.2",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"   </p>",
"   <p>",
"    A subset of patients has been reported with hypocalcemia out of proportion to hypoalbuminemia, due to low serum calcitriol concentrations. These patients have a decline in ionized calcium concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43829/abstract/23,24\">",
"     23,24",
"    </a>",
"    ] and a secondary elevation in serum parathyroid hormone (PTH) concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43829/abstract/25\">",
"     25",
"    </a>",
"    ]. The hyperparathyroidism can then lead to bone disease characterized by mixed osteomalacia and osteitis fibrosa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43829/abstract/22\">",
"     22",
"    </a>",
"    ]. A review of the histologic changes that may be seen can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/43/28343?source=see_link\">",
"     \"Bone biopsy and the diagnosis of renal osteodystrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The frequency with which true hypocalcemia and bone disease occurs in the nephrotic syndrome is unclear, as many investigators have found relatively normal calcium and bone metabolism. One report, for example, evaluated six adults with the nephrotic syndrome and normal renal function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43829/abstract/26\">",
"     26",
"    </a>",
"    ]. Although serum calcidiol concentrations were reduced, the serum ionized calcium, calcitriol, and PTH concentrations were normal, and there was no histologic evidence of bone disease. Other investigators have also noted normal intestinal calcium absorption and bone histology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43829/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In summary, only a subset of patients with the nephrotic syndrome develops clinically important abnormalities in vitamin D, calcium, and bone metabolism. Suggested predisposing factors include increasing age, prolonged duration of disease, renal insufficiency, marked proteinuria, and glucocorticoid therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43829/abstract/11\">",
"     11",
"    </a>",
"    ]. Another possibility which has been demonstrated in experimental animals is impaired production of calcitriol due to tubular damage induced by heavy proteinuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43829/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin D replacement therapy (with ergocalciferol or cholecalciferol) is not routinely recommended in patients with the nephrotic syndrome. It may, however, be beneficial in patients with unremitting or relapsing nephrotic syndrome who have persistent reductions in serum ionized calcium concentrations",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    of abnormal bone histology.",
"   </p>",
"   <p>",
"    The optimal evaluation of calcium and vitamin D metabolism in patients with the nephrotic syndrome is uncertain. We measure serum ionized calcium if the patient has symptoms of hypocalcemia or a low corrected serum calcium concentration from the above formula; measurements of serum PTH may also be useful.",
"   </p>",
"   <p>",
"    If vitamin D is given, oral therapy is probably sufficient. Studies in experimental animals with the nephrotic syndrome have found that calcidiol absorption is normal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43829/abstract/30\">",
"     30",
"    </a>",
"    ]. Similar findings have been noted in humans. In one study, for example, oral administration of calcidiol to nephrotic patients resulted in sustained normalization of the serum calcidiol concentrations and, if renal function was normal, calcitriol; these changes were accompanied by correction of the low serum ionized calcium concentrations and of secondary hyperparathyroidism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43829/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with the nephrotic syndrome who develop chronic renal failure will often be at an increased risk for vitamin D-related bone disease due to the associated reduction in calcitriol synthesis. This is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/35/37434?source=see_link\">",
"     \"Overview of the management of chronic kidney disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/17/32026?source=see_link\">",
"     \"Overview of the management of chronic kidney disease in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The effects of the chronic administration of glucocorticoids on bone mineral density in children with the nephrotic syndrome are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/15/28922?source=see_link\">",
"     \"Treatment of idiopathic nephrotic syndrome in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     GLUCOCORTICOID METABOLISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cortisol-binding globulin also is lost in the urine of nephrotic patients, and serum cortisol concentrations may be reduced. As with T4, however, the percentage of unbound cortisol is increased, serum free cortisol concentrations are normal, and symptomatic hypocortisolism does not occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43829/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17701632\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who have nephrotic syndrome but a relatively normal glomerular filtration rate (GFR) may have low total T4, T3, and reverse T3 (rT3) but normal serum free T4 and T3 concentrations,",
"      <span class=\"nowrap\">",
"       T3/T4",
"      </span>",
"      ratio, and thyrotropin (TSH) concentrations. Such patients are usually clinically euthyroid, and thyroid hormone replacement is generally not required. Thyroid function test abnormalities may be more severe when GFR is reduced. If hypothyroidism is suspected clinically in such a patient, serum TSH should be measured. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Relatively normal glomerular filtration rate'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Renal failure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Glucocorticoids given to treat the nephrotic syndrome can cause low serum T3 and basal serum TSH concentrations and increased serum rT3 concentrations. The serum free T4 concentrations may be the best marker of thyroid status among such patients. Patients with low serum free T4 concentrations should be treated as if they were hypothyroid. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Effect of glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Serum calcidiol (25-hydroxyvitamin D) and calcitriol concentrations may be reduced in patients with nephrotic syndrome, but the physiologically important serum free calcitriol concentration is usually normal. Hypocalcemia is common, however, due to hypoalbuminemia; this does not affect the physiologically important free (or ionized) calcium concentration. We measure serum ionized calcium if the patient has symptoms of hypocalcemia or a low corrected serum calcium concentration from the above formula; measurements of serum parathyroid hormone (PTH) also may be useful. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Vitamin D and calcium metabolism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Vitamin D replacement therapy is not routinely recommended in patients with the nephrotic syndrome. It may be beneficial in patients with persistent reductions in serum ionized calcium concentrations",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      of abnormal bone histology. If vitamin D is given, oral therapy is probably sufficient. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although serum cortisol concentrations may be reduced due to loss of cortisol-binding globulin in the urine, serum free cortisol concentrations are normal, and symptomatic hypocortisolism does not occur. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Glucocorticoid metabolism'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     ACKNOWLEDGMENT",
"    </strong>",
"    &nbsp;&mdash;&nbsp;The author and editors would like to acknowledge Nuhad Ismail, MD, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43829/abstract/1\">",
"      Harris RC, Ismail N. Extrarenal complications of the nephrotic syndrome. Am J Kidney Dis 1994; 23:477.",
"     </a>",
"    </li>",
"    <li>",
"     Helfand M, Crapo LM. Testing for suspected thyroid disease. In: Common Diagnostic Tests: Use and Interpretation, 2nd ed, Sox HC (Ed), American College of Physicians, 1990. p.149.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43829/abstract/3\">",
"      Hoffman AS, Arem R, Eknoyan G. Thyroid function in renal failure. Semin Dial 1988; 1:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43829/abstract/4\">",
"      Crew RJ, Radhakrishnan J, Appel G. Complications of the nephrotic syndrome and their treatment. Clin Nephrol 2004; 62:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43829/abstract/5\">",
"      Afrasiabi MA, Vaziri ND, Gwinup G, et al. Thyroid function studies in the nephrotic syndrome. Ann Intern Med 1979; 90:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43829/abstract/6\">",
"      Gavin LA, McMahon FA, Castle JN, Cavalieri RR. Alterations in serum thyroid hormones and thyroxine-binding globulin in patients with nephrosis. J Clin Endocrinol Metab 1978; 46:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43829/abstract/7\">",
"      Feinstein EI, Kaptein EM, Nicoloff JT, Massry SG. Thyroid function in patients with nephrotic syndrome and normal renal function. Am J Nephrol 1982; 2:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43829/abstract/8\">",
"      Fonseca V, Thomas M, Katrak A, et al. Can urinary thyroid hormone loss cause hypothyroidism? Lancet 1991; 338:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43829/abstract/9\">",
"      Ito S, Kano K, Ando T, Ichimura T. Thyroid function in children with nephrotic syndrome. Pediatr Nephrol 1994; 8:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43829/abstract/10\">",
"      Chadha V, Alon US. Bilateral nephrectomy reverses hypothyroidism in congenital nephrotic syndrome. Pediatr Nephrol 1999; 13:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43829/abstract/11\">",
"      Chopra IJ, Williams DE, Orgiazzi J, Solomon DH. Opposite effects of dexamethasone on serum concentrations of 3,3',5'-triiodothyronine (reverse T3) and 3,3'5-triiodothyronine (T3). J Clin Endocrinol Metab 1975; 41:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43829/abstract/12\">",
"      Kaptein EM. Thyroid function in renal failure. Contrib Nephrol 1986; 50:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43829/abstract/13\">",
"      Illies F, Wingen AM, Bald M, Hoyer PF. Autoimmune thyroiditis in association with membranous nephropathy. J Pediatr Endocrinol Metab 2004; 17:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43829/abstract/14\">",
"      Weetman AP, Pinching AJ, Pussel BA, et al. Membranous glomerulonephritis and autoimmune thyroid disease. Clin Nephrol 1981; 15:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43829/abstract/15\">",
"      Horvath F Jr, Teague P, Gaffney EF, et al. Thyroid antigen associated immune complex glomerulonephritis in Graves' disease. Am J Med 1979; 67:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43829/abstract/16\">",
"      Becker BA, Fenves AZ, Breslau NA. Membranous glomerulonephritis associated with Graves' disease. Am J Kidney Dis 1999; 33:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43829/abstract/17\">",
"      Ploth DW, Fitz A, Schnetzler D, et al. Thyroglobulin-anti-thyroglobulin immune complex glomerulonephritis complicating radioiodine therapy. Clin Immunol Immunopathol 1978; 9:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43829/abstract/18\">",
"      Alon U, Chan JC. Calcium and vitamin D homeostasis in the nephrotic syndrome: current status. Nephron 1984; 36:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43829/abstract/19\">",
"      Sato KA, Gray RW, Lemann J Jr. Urinary excretion of 25-hydroxyvitamin D in health and the nephrotic syndrome. J Lab Clin Med 1982; 99:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43829/abstract/20\">",
"      Barragry JM, France MW, Carter ND, et al. Vitamin-D metabolism in nephrotic syndrome. Lancet 1977; 2:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43829/abstract/21\">",
"      Auwerx J, De Keyser L, Bouillon R, De Moor P. Decreased free 1,25-dihydroxycholecalciferol index in patients with the nephrotic syndrome. Nephron 1986; 42:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43829/abstract/22\">",
"      Koenig KG, Lindberg JS, Zerwekh JE, et al. Free and total 1,25-dihydroxyvitamin D levels in subjects with renal disease. Kidney Int 1992; 41:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43829/abstract/23\">",
"      Goldstein DA, Haldimann B, Sherman D, et al. Vitamin D metabolites and calcium metabolism in patients with nephrotic syndrome and normal renal function. J Clin Endocrinol Metab 1981; 52:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43829/abstract/24\">",
"      Freundlich M, Bourgoignie JJ, Zilleruelo G, et al. Calcium and vitamin D metabolism in children with nephrotic syndrome. J Pediatr 1986; 108:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43829/abstract/25\">",
"      Malluche HH, Goldstein DA, Massry SG. Osteomalacia and hyperparathyroid bone disease in patients with nephrotic syndrome. J Clin Invest 1979; 63:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43829/abstract/26\">",
"      Korkor A, Schwartz J, Bergfeld M, et al. Absence of metabolic bone disease in adult patients with the nephrotic syndrome and normal renal function. J Clin Endocrinol Metab 1983; 56:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43829/abstract/27\">",
"      Mountokalakis Th, Virvidakis C, Singhellakis P, et al. Intestinal calcium absorption in the nephrotic syndrome. Ann Intern Med 1977; 86:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43829/abstract/28\">",
"      Lim P, Jacob E, Tock EP, Pwee HS. Calcium and phosphorus metabolism in nephrotic syndrome. Q J Med 1977; 46:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43829/abstract/29\">",
"      Mizokuchi M, Kubota M, Tomino Y, Koide H. Vitamin D metabolism in nephrotic rats. Contrib Nephrol 1991; 90:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43829/abstract/30\">",
"      Khamiseh G, Vaziri ND, Oveisi F, et al. Vitamin D absorption, plasma concentration and urinary excretion of 25-hydroxyvitamin D in nephrotic syndrome. Proc Soc Exp Biol Med 1991; 196:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43829/abstract/31\">",
"      Haldimann B, Trechsel U. Vitamin D replacement therapy in patients with the nephrotic syndrome. Miner Electrolyte Metab 1983; 9:154.",
"     </a>",
"    </li>",
"    <li>",
"     Bernard D. Metabolic abnormalities in the nephrotic syndrome: Pathophysiology and complications. In: Nephrotic Syndrome, Brenner BM, Stein JH (Eds), Churchill Livingstone, New York 1982. p.85.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3104 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-2.133.93.82-84A455F99E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_51_43829=[""].join("\n");
var outline_f42_51_43829=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17701632\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      THYROID FUNCTION TESTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Relatively normal glomerular filtration rate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Renal failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Effect of glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6339139\">",
"      Kidney disease associated with thyroid dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      VITAMIN D AND CALCIUM METABOLISM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      GLUCOCORTICOID METABOLISM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17701632\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/43/28343?source=related_link\">",
"      Bone biopsy and the diagnosis of renal osteodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/33/3608?source=related_link\">",
"      Laboratory assessment of thyroid function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/41/33430?source=related_link\">",
"      Lipid abnormalities in nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/15/9462?source=related_link\">",
"      Metabolism of vitamin D",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/35/37434?source=related_link\">",
"      Overview of the management of chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/17/32026?source=related_link\">",
"      Overview of the management of chronic kidney disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/25/2453?source=related_link\">",
"      Thyroid function in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/39/44663?source=related_link\">",
"      Thyroid function in nonthyroidal illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/15/28922?source=related_link\">",
"      Treatment of idiopathic nephrotic syndrome in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_51_43830="Overview of thyroiditis";
var content_f42_51_43830=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of thyroiditis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/51/43830/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/51/43830/contributors\">",
"     Kenneth D Burman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/51/43830/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/51/43830/contributors\">",
"     Douglas S Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/51/43830/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/51/43830/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/51/43830/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term thyroiditis encompasses a diverse group of disorders characterized by some form of thyroid inflammation (",
"    <a class=\"graphic graphic_table graphicRef79384 \" href=\"mobipreview.htm?25/55/26492\">",
"     table 1",
"    </a>",
"    ). They include conditions that cause acute illness with severe thyroid pain (eg, subacute thyroiditis and infectious thyroiditis), and conditions in which there is no clinically evident inflammation and the illness is manifested primarily by thyroid dysfunction or goiter (eg, painless thyroiditis and fibrous [Riedel's] thyroiditis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43830/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic review provides an overview of the different types of thyroiditis. These disorders can be categorized in several ways: according to their known or suspected etiology, their pathology, or their clinical features. The approach we use is to categorize thyroiditis according to whether it is associated with thyroid pain and tenderness, because the presence or absence of those findings dominates the major diagnostic considerations (",
"    <a class=\"graphic graphic_table graphicRef79384 \" href=\"mobipreview.htm?25/55/26492\">",
"     table 1",
"    </a>",
"    ). The diagnosis and management of several of the individual disorders, ie, subacute thyroiditis (or subacute granulomatous thyroiditis), painless thyroiditis, and postpartum thyroiditis, are discussed in more detail elsewhere, as is chronic autoimmune thyroiditis (Hashimoto's thyroiditis). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/23/1399?source=see_link\">",
"     \"Subacute thyroiditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/7/24694?source=see_link\">",
"     \"Painless thyroiditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/11/27833?source=see_link\">",
"     \"Pathogenesis of Hashimoto's thyroiditis (chronic autoimmune thyroiditis)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/15/248?source=see_link\">",
"     \"Postpartum thyroiditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NOMENCLATURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is some controversy concerning the nomenclature used to categorize the different forms of thyroiditis. However, most thyroidologists use the term subacute thyroiditis to apply to a specific disease called subacute granulomatous thyroiditis. Infectious thyroiditis is also called suppurative thyroiditis, and painless thyroiditis is also known as silent thyroiditis and lymphocytic thyroiditis with spontaneously resolving hyperthyroidism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     THYROIDITIS WITH THYROID PAIN AND TENDERNESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Causes of this pattern of thyroiditis include subacute, infectious, traumatic, and radiation thyroiditis. Painful Hashimoto's thyroiditis is very rare and in some circumstances has been treated surgically [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43830/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Subacute thyroiditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the hyperthyroid phase, subacute thyroiditis (subacute granulomatous thyroiditis) is characterized by neck pain, a tender diffuse goiter, and elevated T4",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    T3. The classic pattern of changes in thyroid function in patients with subacute is hyperthyroidism, followed by hypothyroidism, and then recovery (",
"    <a class=\"graphic graphic_figure graphicRef75131 \" href=\"mobipreview.htm?28/16/28942\">",
"     figure 1",
"    </a>",
"    ). Hyperthyroidism, when it occurs, is due to damage to thyroid follicular cells and breakdown of stored thyroglobulin, leading to unregulated release of thyroxine (T4) and triiodothyronine (T3). Since ongoing synthesis of the thyroid hormones is inhibited due to TSH suppression and thyroid radioiodine uptake is low during the hyperthyroid phase (in contrast to Graves' hyperthyroidism), the hyperthyroidism lasts only until the stores of T4 and T3 are depleted, usually two to six weeks. Hypothyroidism is also usually transient, but can occasionally be permanent.",
"   </p>",
"   <p>",
"    Other names for this disorder include subacute nonsuppurative thyroiditis, de Quervain's thyroiditis, or subacute granulomatous thyroiditis. It is presumed to be caused by a viral infection or postviral inflammatory process, because many patients have a history of an upper respiratory infection preceding the onset of thyroiditis, and clusters of cases have occurred in association with epidemics of Coxsackievirus or other viral infections. There is a strong association with HLA-B35. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/23/1399?source=see_link\">",
"     \"Subacute thyroiditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Infectious thyroiditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infectious thyroiditis may be either acute or chronic. Acute infections, with abscess formation, may be caused by gram-positive or gram-negative organisms, which reach the thyroid either via hematogenous spread, usually in an immunocompromised patient, or via a fistula from the piriform sinus adjacent to the larynx [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43830/abstract/4\">",
"     4",
"    </a>",
"    ]. The latter is probably the most common cause of suppurative thyroiditis, and it usually occurs in children. The organisms most commonly reported to cause acute infectious thyroiditis are Staphylococcus and Streptococcus, but many other pathogens have also been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43830/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Other infections of the thyroid, including mycobacterial, fungal, and Pneumocystis infections, are more chronic, and these infections occur most frequently in immunocompromised patients.",
"   </p>",
"   <p>",
"    Acute infectious thyroiditis is characterized by the sudden onset of neck pain and tenderness that is usually unilateral and is accompanied by fever, chills, and other symptoms and signs of infection. Most patients have a unilateral neck mass, which may be fluctuant. Acute neck pain and tenderness and a thyroid mass may also be caused by hemorrhage into a thyroid nodule and subacute thyroiditis. Thyroid function in patients with acute infectious thyroiditis is usually normal but thyrotoxicosis may be present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43830/abstract/4\">",
"     4",
"    </a>",
"    ]. Thyroid ultrasound can differentiate between subacute thyroiditis (diffuse heterogeneity and low intensity vascular flow) and infectious thyroiditis (abscess), as can fine needle aspiration biopsy (multinucleated giant cell granulomas in subacute thyroiditis versus fluid collection with microbes on bacteriologic examination in infectious thyroiditis).",
"   </p>",
"   <p>",
"    A patient who has a painful tender thyroid mass should be evaluated immediately with clinical examination, ultrasonography, and needle aspiration of the mass, followed by drainage and antibiotic therapy according to the results of studies of the fluid obtained from the neck mass or of blood or other cultures. Ultrasonography or other imaging studies should be performed to confirm the presence of a single abscess and to confirm the diagnosis. In most instances, rapid diagnosis and treatment is required. Intravenous antibiotics are generally preferred over oral antibiotics as initial treatment for acute bacterial thyroiditis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43830/abstract/4\">",
"     4",
"    </a>",
"    ]. Infrequently, surgical drainage or removal is required in patients who do not respond to percutaneous drainage and systemic antibiotic therapy.",
"   </p>",
"   <p>",
"    Patients with more chronic thyroid infections often have bilateral disease. Thyroid pain and tenderness are less prominent than with acute infections, and some patients have hypothyroidism. The essential steps in evaluation are aspiration biopsy of the thyroid to identify the causative organism and radiologic studies to identify fistulae or tracts contributing to the disease process and to confirm the diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Radiation thyroiditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;An occasional patient with hyperthyroidism caused by Graves' disease, who is treated with radioiodine, develops thyroid pain and tenderness 5 to 10 days later, due to radiation-induced injury and necrosis of thyroid follicular cells and associated inflammation. The neck pain and tenderness are usually mild and subside spontaneously in a few days to one week. There also may be transient exacerbation of the hyperthyroidism. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/7/12410?source=see_link&amp;anchor=H30632421#H30632421\">",
"     \"Radioiodine in the treatment of hyperthyroidism\", section on 'Adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Palpation- or trauma-induced thyroiditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vigorous palpation of the thyroid gland during physical examination, manipulation of the gland during thyroid biopsy or neck surgery, especially parathyroid surgery, or even trauma (ie, from an automobile seat belt) can cause thyroiditis, manifested by transient neck pain and tenderness and transient hyperthyroidism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43830/abstract/6-10\">",
"     6-10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     THYROIDITIS WITHOUT PAIN AND TENDERNESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Causes of this pattern of thyroiditis include painless, postpartum, drug-induced, and fibrous thyroiditis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Painless thyroiditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Painless thyroiditis is characterized primarily by transient hyperthyroidism, followed sometimes by hypothyroidism, and then recovery (",
"    <a class=\"graphic graphic_figure graphicRef75131 \" href=\"mobipreview.htm?28/16/28942\">",
"     figure 1",
"    </a>",
"    ). It is also known as silent thyroiditis and lymphocytic thyroiditis with spontaneously resolving hyperthyroidism.",
"   </p>",
"   <p>",
"    Painless thyroiditis accounts for 1 to 5 percent of cases of hyperthyroidism. It is considered a variant form of chronic autoimmune thyroiditis (Hashimoto's thyroiditis), suggesting that it is part of the spectrum of thyroid autoimmune disease. It can also be caused by administration of interferon-alfa, interleukin-2, or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    administration, although the pathogenesis of these disorders may be different. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Drug-induced thyroiditis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Painless thyroiditis should be considered as the cause of hyperthyroidism in any woman (who is not postpartum) or man who has had symptoms for less than two months and has a small diffuse goiter or no thyroid enlargement. The key clinical findings are mild hyperthyroidism of short duration, little or no thyroid enlargement, and no Graves' ophthalmopathy or pretibial myxedema. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/7/24694?source=see_link\">",
"     \"Painless thyroiditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Postpartum thyroiditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postpartum thyroiditis is similar clinically and pathogenetically to painless thyroiditis except that, by definition, it occurs in women within one year after parturition (or after spontaneous or induced abortion). Based upon biochemical studies, it occurs after about 8 to 10 percent of pregnancies, although the number of women with clinically evident thyroid disease is lower. In clinically hyperthyroid women, it must be distinguished from postpartum exacerbations of Graves' disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/15/248?source=see_link\">",
"     \"Postpartum thyroiditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Postpartum thyroiditis differs from painless thyroiditis in that more patients have elevated levels of serum antithyroid antibody (ie, antithyroglobulin or antithyroid peroxidase antibodies) concentrations, the concentrations are higher, and the likelihood of permanent thyroid disease later is greater. This apparent difference may reflect the greater ease of studying postpartum women prospectively than women in the general population. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/7/24694?source=see_link\">",
"     \"Painless thyroiditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Drug-induced thyroiditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients receiving interferon-alfa, interleukin-2,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    may develop thyroiditis without pain. Its occurrence in patients receiving these drugs does not seem coincidental, but only for interferon-alfa are there sufficient data to indicate and be confident of a causative relationship.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Interferon-alfa",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyroid disorders are common in patients with chronic hepatitis C virus (HCV) infection, particularly women. In addition, many patients with HCV infection develop thyroid disease during interferon-alfa therapy.",
"   </p>",
"   <p>",
"    The most common interferon-alfa-associated thyroid abnormality is the development of de novo antithyroid antibodies without clinical disease (5 to 15 percent). Approximately 5 to 10 percent of patients develop clinical thyroid disease, including painless thyroiditis, Hashimoto's thyroiditis, or Graves' disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/41/36505?source=see_link\">",
"     \"Principles of interferon therapy in liver disease and the induction of autoimmunity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These changes usually appear after three months of therapy, but can occur as long as interferon-alfa is given. The risk of any form of thyroid dysfunction is greater in those patients who have increased serum antithyroid antibody concentrations before initiation of interferon-alfa, a finding that suggests that it in some way exacerbates underlying thyroid autoimmune disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/41/36505?source=see_link\">",
"     \"Principles of interferon therapy in liver disease and the induction of autoimmunity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/9/16538?source=see_link\">",
"     \"Management of the side effects of peginterferon and ribavirin being used for treatment of chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Interleukin-2",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with metastatic cancer and leukemia are sometimes treated with interleukin-2, usually in combination with other cytokines or anticancer drugs. In several studies, a syndrome mimicking painless thyroiditis occurred in about 2 percent of the patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43830/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Denileukin diftitox",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/57/918?source=see_link\">",
"     Denileukin diftitox",
"    </a>",
"    (dd) is a fusion protein of diphtheria toxin and the ligand-binding domain of IL-2 used to treat mycosis fungoides and other T-cell disorders. Eight patients have been reported with thyrotoxicosis after treatment, radioiodine uptakes were assessed in two patients and low in both, consistent with thyroiditis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43830/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Amiodarone",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     Amiodarone",
"    </a>",
"    is an antiarrhythmic drug that contains 37 percent iodine. As a result, it can affect thyroid function in several different ways:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"       Amiodarone",
"      </a>",
"      can cause hyperthyroidism. There are two types of amiodarone-induced thyrotoxicosis (AIT). In type 1, there is increased synthesis of thyroid hormone (usually in patients with a preexisting nodular goiter), whereas in type 2, there is excess release of T4 and T3 due to a destructive thyroiditis. These types differ in their pathogenesis, management, and outcome.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"       Amiodarone",
"      </a>",
"      can cause hypothyroidism via the antithyroid action of iodine (especially in patients with preexisting thyroid disease).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical manifestations and treatment of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    -induced thyroid dysfunction are reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/30/25065?source=see_link\">",
"     \"Amiodarone and thyroid dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Lithium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with depression who are treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    have an increased incidence of hyperthyroidism. In a retrospective study of patients with Graves&rsquo; hyperthyroidism and painless thyroiditis, the odds of lithium exposure were higher in patients with painless thyroiditis as compared with those with Graves&rsquo;s disease (odds of exposure 4.7, 95% CI 1.3-17.1) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43830/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/29/42453?source=see_link&amp;anchor=H6#H6\">",
"     \"Lithium and the thyroid\", section on 'Hyperthyroidism'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Kinase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tyrosine kinase inhibitors are used to treat a variety of disorders (eg, gastrointestinal stromal tumors, renal cell carcinoma). In euthyroid patients with intact thyroid glands, these agents have been associated with the development of hypothyroidism and an elevated TSH in approximately 50 to 70 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43830/abstract/15\">",
"     15",
"    </a>",
"    ]. Hypothyroidism has been most frequently reported with sunitinib but it appears to be a class effect and probably can occur with any tyrosine kinase inhibitor. Hyperthyroidism, possibly from a destructive thyroiditis, has also been reported. This topic is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43882?source=see_link&amp;anchor=H1651229244#H1651229244\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\", section on 'Thyroid dysfunction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Fibrous thyroiditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibrous thyroiditis, also known as Riedel's thyroiditis or invasive thyroiditis, is characterized by extensive fibrosis and macrophage and eosinophil infiltration of the thyroid gland that extends into adjacent tissues [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43830/abstract/16\">",
"     16",
"    </a>",
"    ]. It is probably a primary fibrosing disorder, and has been reported in patients who also had mediastinal and retroperitoneal fibrosis.",
"   </p>",
"   <p>",
"    Affected patients have neck discomfort or tightness, sometimes dysphagia or hoarseness, and a diffuse, although occasionally asymmetric, goiter that is very hard, fixed, and often not clearly separable from the adjacent tissues. Most patients are euthyroid, but a few are hypothyroid, and serum antithyroid antibody concentrations are often high. The diagnosis is established by thyroid biopsy. Patients should be evaluated for evidence of systemic fibrosis in other areas, such as mediastinum and retroperitoneal ares.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     Prednisone",
"    </a>",
"    therapy may alleviate local symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43830/abstract/17\">",
"     17",
"    </a>",
"    ]. In a small case series,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    appeared to be effective in delaying, or perhaps even helping resolve, the progression of disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43830/abstract/18\">",
"     18",
"    </a>",
"    ]. Surgery should only be undertaken after contemplation of the risks and benefits. However, surgery may be indicated to relieve tracheal or esophageal compression and occasionally to exclude carcinoma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/15/43257?source=see_link&amp;anchor=H2#H2\">",
"     \"Infiltrative thyroid disease\", section on 'Riedel's thyroiditis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?5/50/5922?source=see_link\">",
"       \"Patient information: Thyroiditis after pregnancy (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9708206\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The term thyroiditis encompasses a diverse group of disorders characterized by some form of thyroid inflammation (",
"      <a class=\"graphic graphic_table graphicRef79384 \" href=\"mobipreview.htm?25/55/26492\">",
"       table 1",
"      </a>",
"      ). The classic pattern of changes in thyroid function in patients with subacute and painless thyroiditis is hyperthyroidism, followed by hypothyroidism and then recovery. Hyperthyroidism, when it occurs, is due to damage to thyroid follicular cells and breakdown of stored thyroglobulin, leading to unregulated release of thyroxine (T4) and triiodothyronine (T3). Hyperthyroidism lasts only until the stores of T4 and T3 are depleted, usually two to six weeks. Hypothyroidism is also usually transient, but can rarely be permanent. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Thyroiditis that presents with thyroid pain and tenderness is typically caused by subacute thyroiditis and less frequently by infectious or traumatic etiologies. It may also occur after radioiodine therapy. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Thyroiditis with thyroid pain and tenderness'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Painless thyroiditis is often autoimmune mediated and can also occur after exposure to certain drugs, such as interferon-alpha, interleukin-2, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Thyroiditis without pain and tenderness'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Drug-induced thyroiditis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Lazarus JH. Silent thyroiditis and subacute thyroiditis. In: The thyroid: A fundamental and clinical text, 7th, Braverman LE, Utiger RD (Eds), Lippincott-Raven, Philadelphia 1996. p.577.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43830/abstract/2\">",
"      Pearce EN, Farwell AP, Braverman LE. Thyroiditis. N Engl J Med 2003; 348:2646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43830/abstract/3\">",
"      Kon YC, DeGroot LJ. Painful Hashimoto's thyroiditis as an indication for thyroidectomy: clinical characteristics and outcome in seven patients. J Clin Endocrinol Metab 2003; 88:2667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43830/abstract/4\">",
"      Paes JE, Burman KD, Cohen J, et al. Acute bacterial suppurative thyroiditis: a clinical review and expert opinion. Thyroid 2010; 20:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43830/abstract/5\">",
"      McLaughlin SA, Smith SL, Meek SE. Acute suppurative thyroiditis caused by Pasteurella multocida and associated with thyrotoxicosis. Thyroid 2006; 16:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43830/abstract/6\">",
"      Kobayashi A, Kuma K, Matsuzuka F, et al. Thyrotoxicosis after needle aspiration of thyroid cyst. J Clin Endocrinol Metab 1992; 75:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43830/abstract/7\">",
"      Leckie RG, Buckner AB, Bornemann M. Seat belt-related thyroiditis documented with thyroid Tc-99m pertechnetate scans. Clin Nucl Med 1992; 17:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43830/abstract/8\">",
"      Stang MT, Yim JH, Challinor SM, et al. Hyperthyroidism after parathyroid exploration. Surgery 2005; 138:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43830/abstract/9\">",
"      Mai VQ, Glister BC, Clyde PW, Shakir KM. Palpation thyroiditis causing new-onset atrial fibrillation. Thyroid 2008; 18:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43830/abstract/10\">",
"      Espiritu RP, Dean DS. Parathyroidectomy-induced thyroiditis. Endocr Pract 2010; 16:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43830/abstract/11\">",
"      Schwartzentruber DJ, White DE, Zweig MH, et al. Thyroid dysfunction associated with immunotherapy for patients with cancer. Cancer 1991; 68:2384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43830/abstract/12\">",
"      Vialettes B, Guillerand MA, Viens P, et al. Incidence rate and risk factors for thyroid dysfunction during recombinant interleukin-2 therapy in advanced malignancies. Acta Endocrinol (Copenh) 1993; 129:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43830/abstract/13\">",
"      Ghori F, Polder KD, Pinter-Brown LC, et al. Thyrotoxicosis after denileukin diftitox therapy in patients with mycosis fungoides. J Clin Endocrinol Metab 2006; 91:2205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43830/abstract/14\">",
"      Miller KK, Daniels GH. Association between lithium use and thyrotoxicosis caused by silent thyroiditis. Clin Endocrinol (Oxf) 2001; 55:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43830/abstract/15\">",
"      Mannavola D, Coco P, Vannucchi G, et al. A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J Clin Endocrinol Metab 2007; 92:3531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43830/abstract/16\">",
"      Heufelder AE, Goellner JR, Bahn RS, et al. Tissue eosinophilia and eosinophil degranulation in Riedel's invasive fibrous thyroiditis. J Clin Endocrinol Metab 1996; 81:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43830/abstract/17\">",
"      Zimmermann-Belsing T, Feldt-Rasmussen U. Riedel's thyroiditis: an autoimmune or primary fibrotic disease? J Intern Med 1994; 235:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43830/abstract/18\">",
"      Few J, Thompson NW, Angelos P, et al. Riedel's thyroiditis: treatment with tamoxifen. Surgery 1996; 120:993.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7824 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-A7B94B43F3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_51_43830=[""].join("\n");
var outline_f42_51_43830=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9708206\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NOMENCLATURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      THYROIDITIS WITH THYROID PAIN AND TENDERNESS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Subacute thyroiditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Infectious thyroiditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Radiation thyroiditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Palpation- or trauma-induced thyroiditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      THYROIDITIS WITHOUT PAIN AND TENDERNESS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Painless thyroiditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Postpartum thyroiditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Drug-induced thyroiditis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Interferon-alfa",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Interleukin-2",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Denileukin diftitox",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Amiodarone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Lithium",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Kinase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Fibrous thyroiditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9708206\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7824\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7824|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/16/28942\" title=\"figure 1\">",
"      Course of thyroiditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7824|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?25/55/26492\" title=\"table 1\">",
"      Causes of thyroiditis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/30/25065?source=related_link\">",
"      Amiodarone and thyroid dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/15/43257?source=related_link\">",
"      Infiltrative thyroid disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/29/42453?source=related_link\">",
"      Lithium and the thyroid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/9/16538?source=related_link\">",
"      Management of the side effects of peginterferon and ribavirin being used for treatment of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/7/24694?source=related_link\">",
"      Painless thyroiditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/11/27833?source=related_link\">",
"      Pathogenesis of Hashimoto's thyroiditis (chronic autoimmune thyroiditis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?5/50/5922?source=related_link\">",
"      Patient information: Thyroiditis after pregnancy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/15/248?source=related_link\">",
"      Postpartum thyroiditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/41/36505?source=related_link\">",
"      Principles of interferon therapy in liver disease and the induction of autoimmunity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/7/12410?source=related_link\">",
"      Radioiodine in the treatment of hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/23/1399?source=related_link\">",
"      Subacute thyroiditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43882?source=related_link\">",
"      Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_51_43831="Skin abscesses, furuncles, and carbuncles";
var content_f42_51_43831=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Skin abscesses, furuncles, and carbuncles",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/51/43831/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/51/43831/contributors\">",
"     Larry M Baddour, MD, FIDSA",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/51/43831/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/51/43831/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/51/43831/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/51/43831/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/51/43831/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/51/43831/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 23, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin abscesses are collections of pus within the dermis and deeper skin tissues. A furuncle (or \"boil\") is an infection of the hair follicle in which purulent material extends through the dermis into the subcutaneous tissue, where a small abscess forms. A carbuncle is a coalescence of several inflamed follicles into a single inflammatory mass with purulent drainage from multiple follicles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43831/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most abscesses are caused by infection. However, sterile abscesses can occur in the setting of injected irritants. Examples include injected drugs (particularly oil based ones) that may not be fully absorbed and so remain at the site of injection, causing local irritation. Sterile abscesses can turn into hard, solid lesions as they scar.",
"   </p>",
"   <p>",
"    The epidemiology, clinical manifestations, microbiology and treatment of skin abscesses, furuncles, and carbuncles due to infection will be reviewed here. Issues related to dental, vulvovaginal, and perianal abscesses are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/53/20313?source=see_link\">",
"     \"Complications, diagnosis, and treatment of odontogenic infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/40/26246?source=see_link\">",
"     \"Perianal abscess: Clinical manifestations, diagnosis, treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/54/22375?source=see_link\">",
"     \"Disorders of Bartholin gland\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin abscesses, furuncles, and carbuncles can develop in healthy individuals with no predisposing conditions other than skin or nasal carriage of Staphylococcus aureus; spontaneous infection due to community-acquired methicillin-resistant S. aureus (CA-MRSA) may occur with greater frequency than abscesses due to other pathogens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43831/abstract/2\">",
"     2",
"    </a>",
"    ]. Rectal colonization of S. aureus, including CA-MRSA of the USA300 clone, was strongly associated with skin abscess formation in one pediatric investigation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43831/abstract/3\">",
"     3",
"    </a>",
"    ]. Individuals in close contact with others who have active infection with skin abscesses, furuncles, and carbuncles are at increased risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43831/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Individuals exposed to whirlpool footbaths at nail salons are at risk for mycobacterial furunculosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43831/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Additional risk factors include diabetes mellitus and immunologic abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43831/abstract/6,8\">",
"     6,8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/26/43433?source=see_link\">",
"     \"Approach to the adult with recurrent infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/47/30458?source=see_link\">",
"     \"Approach to the child with recurrent infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/53/8026?source=see_link\">",
"     \"Epidemiology of methicillin-resistant Staphylococcus aureus infection in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/21/30042?source=see_link&amp;anchor=H12#H12\">",
"     \"Epidemiology and clinical spectrum of methicillin-resistant Staphylococcus aureus infections in children\", section on 'Epidemiology and risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Any process leading to a breach in the skin barrier can also predispose to the development of a skin abscesses, furuncle, or carbuncle. Examples include primary dermatologic conditions as well as trauma related to abrasions, shaving, and insect bites. In addition, intravenous drug users are at particular risk due to needle injection, including either intravenous injection or subcutaneous and intramuscular injection (\"skin popping\") [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43831/abstract/9-11\">",
"     9-11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Skin abscesses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin abscesses are collections of pus within the dermis and deeper skin tissues. Skin abscesses manifest as painful, tender, fluctuant and erythematous nodules, frequently surmounted by a pustule and surrounded by a rim of erythematous swelling (",
"    <a class=\"graphic graphic_picture graphicRef53261 \" href=\"mobipreview.htm?19/51/20287\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43831/abstract/12\">",
"     12",
"    </a>",
"    ]. Spontaneous drainage of purulent material may occur, and regional adenopathy may be observed. Fever, chills and systemic toxicity are unusual.",
"   </p>",
"   <p>",
"    Skin abscess may arise as a result of bacteremia, and bacteremia may arise as result of skin abscess. Sequelae of bacteremia related to skin abscess include metastatic sites of infection such as endocarditis and osteomyelitis.",
"   </p>",
"   <p>",
"    Ultrasound may be useful for distinguishing skin abscesses from other lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43831/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Furuncles and carbuncles",
"    </span>",
"    &nbsp;&mdash;&nbsp;A furuncle (or \"boil\") is an infection of the hair follicle in which purulent material extends through the dermis into the subcutaneous tissue, where a small abscess forms. Furuncles can occur anywhere on hairy skin and usually follow an episode of folliculitis. A carbuncle is a coalescence of several inflamed follicles into a single inflammatory mass with purulent drainage from multiple follicles (",
"    <a class=\"graphic graphic_picture graphicRef70089 \" href=\"mobipreview.htm?35/13/36048\">",
"     picture 2",
"    </a>",
"    ). Systemic symptoms are more common in the setting of carbuncles than furuncles.",
"   </p>",
"   <p>",
"    Furuncles and carbuncles arise when areas of skin containing hair follicles are exposed to friction and perspiration. Common areas of involvement include the back of the neck, face, axillae and buttocks. Furuncles and carbuncles are usually attributable to S. aureus; culprits include both methicillin-susceptible and methicillin-resistant S. aureus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43831/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rarely, infections involving the medial third of the face (ie, the areas around the eyes and nose) can be complicated by septic cavernous thrombosis, since the veins in this region are valveless (",
"    <a class=\"graphic graphic_figure graphicRef55404 \" href=\"mobipreview.htm?40/19/41279\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/38/23145?source=see_link\">",
"     \"Septic dural sinus thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other skin lesions that should be distinguished from skin abscesses, furuncles, and carbuncles include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Folliculitis (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/55/22387?source=see_link\">",
"       \"Folliculitis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Hidradenitis suppurativa (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/7/6265?source=see_link\">",
"       \"Pathogenesis, clinical features, and diagnosis of hidradenitis suppurativa\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Sporotrichosis (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/11/12469?source=see_link\">",
"       \"Clinical features and diagnosis of sporotrichosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Leishmaniasis (see",
"      <a class=\"medical medical_review\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis?source=see_link\">",
"       \"Clinical manifestations and diagnosis of cutaneous leishmaniasis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Tularemia (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/10/30888?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and treatment of tularemia\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Myiasis (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/43/20152?source=see_link\">",
"       \"Skin lesions in the returning traveler\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Botryomycosis (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/37/33365?source=see_link\">",
"       \"Botryomycosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Nontuberculous mycobacteria (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/25/5530?source=see_link\">",
"       \"Rapidly growing mycobacterial infections in HIV-negative patients\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Blastomycosis (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/4/79?source=see_link\">",
"       \"Mycology, pathogenesis, and epidemiology of blastomycosis\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Skin lesions in immunocompromised individuals should prompt consideration of additional pathogens including Nocardia and cryptococcus. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/34/42537?source=see_link\">",
"     \"Infectious causes of fever and rash in non-HIV immunocompromised hosts\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin abscesses can be due to one or more than one pathogen and may include skin flora as well as organisms from adjacent mucous membranes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43831/abstract/12,16-18\">",
"     12,16-18",
"    </a>",
"    ]. S. aureus monoinfection (either methicillin-susceptible or methicillin-resistant S. aureus) occurs in up to 75 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43831/abstract/1,12,19-22\">",
"     1,12,19-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Isolation of multiple organisms (including gram-negatives and anaerobes) is more common in patients with skin abscess involving the perioral, perirectal or vulvovaginal areas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43831/abstract/12\">",
"     12",
"    </a>",
"    ]. Organisms of oral origin, including anaerobes, are seen most frequently among intravenous drug users [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43831/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/53/8026?source=see_link\">",
"     \"Epidemiology of methicillin-resistant Staphylococcus aureus infection in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/40/26246?source=see_link\">",
"     \"Perianal abscess: Clinical manifestations, diagnosis, treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/21/30042?source=see_link&amp;anchor=H8#H8\">",
"     \"Epidemiology and clinical spectrum of methicillin-resistant Staphylococcus aureus infections in children\", section on 'Microbiologic characteristics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additional pathogens implicated in folliculitis can cause furuncles and carbuncles, given that all three syndromes are related to hair follicle involvement. Such pathogens include Pseudomonas, Candida spp, and others. Individuals exposed to whirlpool footbaths at nail salons are at risk for mycobacterial furunculosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43831/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/55/22387?source=see_link&amp;anchor=H4#H4\">",
"     \"Folliculitis\", section on 'Microbiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Incision and drainage",
"    </span>",
"    &nbsp;&mdash;&nbsp;For small furuncles, warm compresses to promote drainage are usually sufficient treatment. Larger furuncles, carbuncles and abscesses require incision and drainage, and material should be sent for culture and susceptibility testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43831/abstract/23\">",
"     23",
"    </a>",
"    ]. Although cultures were not obtained routinely prior to the emergence of MRSA, the microbiology data are important for both clinicians and epidemiologists to guide antimicrobial therapy, prevention, and control measures. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/46/5865?source=see_link\">",
"     \"Technique of incision and drainage for skin abscess\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Individuals at risk for endocarditis should receive antimicrobial prophylaxis prior to incision and drainage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43831/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. If possible,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    (1 g intravenously 60 minutes before the procedure) is preferred; if intravenous administration is not feasible, a single dose of an oral agent with activity against MRSA is acceptable (",
"    <a class=\"graphic graphic_table graphicRef57196 \" href=\"mobipreview.htm?39/12/40139\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef64178 \" href=\"mobipreview.htm?9/57/10140\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef63973 \" href=\"mobipreview.htm?2/60/3020\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/36/585?source=see_link\">",
"     \"Antimicrobial prophylaxis for bacterial endocarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/7/4216?source=see_link\">",
"     \"Treatment of skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/32/33290?source=see_link&amp;anchor=H8#H8\">",
"     \"Evaluation and management of suspected methicillin-resistant Staphylococcus aureus skin and soft tissue infections in children\", section on 'Antimicrobial therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Role of antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of ancillary antimicrobial therapy in the treatment of skin abscesses, furuncles, and carbuncles is uncertain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43831/abstract/26\">",
"     26",
"    </a>",
"    ]. Although older studies have demonstrated no significant benefit to ancillary antibiotic therapy over incision and drainage alone, the emergence of MRSA has prompted reconsideration of the importance of antimicrobial therapy in addition to incision and drainage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43831/abstract/21,27-29\">",
"     21,27-29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some studies suggest that incision and drainage alone may be sufficient for immunocompetent patients with skin abscesses due to MRSA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43831/abstract/1,2,19,21,29-31\">",
"     1,2,19,21,29-31",
"    </a>",
"    ]. This was illustrated in an observational study of 69 children with skin and soft tissue abscesses due to MRSA. Most underwent drainage; 58 patients who inadvertently received antibiotics without MRSA activity responded as well as 21 patients treated with antibiotics possessing MRSA activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43831/abstract/2\">",
"     2",
"    </a>",
"    ]. Similar findings were described in a trial of 166 adults with skin abscesses who underwent incision and drainage and were subsequently randomized to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/37/37462?source=see_link\">",
"     cephalexin",
"    </a>",
"    or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43831/abstract/19\">",
"     19",
"    </a>",
"    ]. Among the 85 patients with MRSA positive cultures, cure rates were comparable for both groups (84 and 90 percent, respectively).",
"   </p>",
"   <p>",
"    However, other data suggest that patients with skin infection due to MRSA benefit from treatment with drainage as well as antibiotics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43831/abstract/20,32\">",
"     20,32",
"    </a>",
"    ]. In a retrospective study of 531 cases of soft tissue infection due to MRSA (including 361 skin abscesses); incision and drainage was performed in 80 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43831/abstract/20\">",
"     20",
"    </a>",
"    ]. Patients treated with antimicrobial therapy to which the isolate was susceptible in vitro had more successful outcomes than those not treated with active antimicrobial therapy (95 versus 87 percent, respectively).",
"   </p>",
"   <p>",
"    It is uncertain whether antimicrobial therapy decreases the risk of recurrent infection. Two randomized trials (one that included adults and one that included children) showed that the likelihood of recurrent abscess formation was lower in patients who received",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    than in patients who received placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43831/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To avoid overuse of the available agents with activity against MRSA, which could result in an increased prevalence of resistance to these agents, results of additional large randomized trials are needed to address the role of ancillary antibiotic therapy in skin abscess. &nbsp;",
"   </p>",
"   <p>",
"    In the meantime, we suggest that patients with abscess &gt;5 cm, multiple lesions, extensive surrounding cellulitis, associated comorbidities or immunosuppression, systemic signs of infection, or lack of response to incision and drainage be managed with incision and drainage as well as antimicrobial therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43831/abstract/1,35\">",
"     1,35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/7/4216?source=see_link\">",
"     \"Treatment of skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Antibiotic selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Empiric antibiotic therapy for skin abscesses, furuncles, and carbuncles should include activity against MRSA in areas of high MRSA prevalence (",
"    <a class=\"graphic graphic_table graphicRef53504 \" href=\"mobipreview.htm?5/9/5275\">",
"     table 4",
"    </a>",
"    ). Patients with localized disease who appear otherwise well may be managed as outpatients with oral therapy; appropriate oral agents are shown in the Tables and discussed in detail separately (",
"    <a class=\"graphic graphic_table graphicRef64178 \" href=\"mobipreview.htm?9/57/10140\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef63973 \" href=\"mobipreview.htm?2/60/3020\">",
"     table 3",
"    </a>",
"    ). Empiric therapy selection should be tailored to culture and susceptibility results when available. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/7/4216?source=see_link\">",
"     \"Treatment of skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/32/33290?source=see_link&amp;anchor=H8#H8\">",
"     \"Evaluation and management of suspected methicillin-resistant Staphylococcus aureus skin and soft tissue infections in children\", section on 'Antimicrobial therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with evidence of extensive skin involvement or systemic toxicity should receive parenteral antimicrobial therapy that includes empiric coverage for gram-positive pathogens including MRSA as well as gram-negative and anaerobic organisms, pending culture and susceptibility results. The appropriate initial choice for parenteral treatment of MRSA is",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    ; alternative parenteral agents with activity against MRSA for adults are shown in the Table and discussed in detail separately (",
"    <a class=\"graphic graphic_table graphicRef57196 \" href=\"mobipreview.htm?39/12/40139\">",
"     table 1",
"    </a>",
"    ). Options for gram-negative and anaerobic coverage are outlined in the Table (",
"    <a class=\"graphic graphic_table graphicRef67894 \" href=\"mobipreview.htm?7/21/7517\">",
"     table 5",
"    </a>",
"    ). Parenteral agents for children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/48/21258?source=see_link\">",
"     \"Treatment of invasive methicillin-resistant Staphylococcus aureus infections in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/6/29802?source=see_link&amp;anchor=H11#H11\">",
"     \"Treatment of invasive methicillin-resistant Staphylococcus aureus infection in children\", section on 'Treatment approach'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The duration of antimicrobial therapy should be tailored to clinical improvement; about five to seven days is usually sufficient. Longer duration of therapy may be warranted for patients with severe disease; in such cases, duration should be tailored to clinical resolution of symptoms. Patients treated initially with parenteral therapy with resolving signs of infection may complete antimicrobial therapy with an oral agent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     RECURRENT INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent infection may occur as a result of recurrent epidemiologic risk",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    host immunosuppression. Preventive measures for reducing the spread of staphylococci may be helpful for reducing risk for recurrent skin infection and are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/59/17338?source=see_link\">",
"     \"Prevention and control of methicillin-resistant Staphylococcus aureus in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Immunosuppression predisposing to recurrent skin infection may be inherited or acquired. Inherited conditions are discussed in detail separately. Patients with risk factors for acquired immunosuppressive conditions predisposing to infection (such as diabetes or HIV infection) should undergo screening for these conditions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/26/43433?source=see_link&amp;anchor=H18#H18\">",
"     \"Approach to the adult with recurrent infections\", section on 'Abscess'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/47/30458?source=see_link\">",
"     \"Approach to the child with recurrent infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/16/2312?source=see_link\">",
"     \"Screening for diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/55/20345?source=see_link\">",
"     \"Diagnostic assays for HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/63/20465?source=see_link\">",
"       \"Patient information: Boil (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Skin abscesses are collections of pus within the dermis and deeper skin tissues. They manifest as painful, tender, fluctuant, and erythematous nodules, frequently surmounted by a pustule and surrounded by a rim of erythematous swelling. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A furuncle is an infection of the hair follicle in which purulent material extends through the dermis into the subcutaneous tissue, where a small abscess forms. A carbuncle is a coalescence of several inflamed follicles into a single inflammatory mass with purulent drainage from multiple follicles. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Risk factors for developing skin abscesses, furuncles, and carbuncles include diabetes mellitus, immunologic abnormalities, and breaches to the skin barrier. However, healthy individuals with no risk factors may also develop these infections. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Skin abscesses, furuncles, and carbuncles may be polymicrobial or monomicrobial. S. aureus infection occurs in up to one-half of cases. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For small furuncles, warm compresses to promote drainage are usually sufficient treatment. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that patients with skin abscesses, furuncles, and carbuncles undergo incision and drainage (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). Debrided material should be sent for culture and susceptibility testing. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Incision and drainage'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The role of ancillary antimicrobial therapy in the treatment of skin abscess is uncertain; incision and drainage alone may be sufficient, although some data suggest that antimicrobial therapy is beneficial. For otherwise healthy patients with skin abscess, we suggest incision and drainage and no antimicrobial therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). For patients with abscess &gt;5 cm, multiple lesions, extensive surrounding cellulitis, immunocompromise, or systemic signs of infection, we recommend both incision and drainage and antimicrobial therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Role of antibiotics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antibiotic selection and duration of therapy is as outlined above. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Antibiotic selection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Preventive measures for reducing the spread of staphylococci may be helpful for reducing risk for recurrent skin abscesses and are discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/59/17338?source=see_link\">",
"       \"Prevention and control of methicillin-resistant Staphylococcus aureus in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43831/abstract/1\">",
"      Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005; 41:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43831/abstract/2\">",
"      Lee MC, Rios AM, Aten MF, et al. Management and outcome of children with skin and soft tissue abscesses caused by community-acquired methicillin-resistant Staphylococcus aureus. Pediatr Infect Dis J 2004; 23:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43831/abstract/3\">",
"      Faden H, Lesse AJ, Trask J, et al. Importance of colonization site in the current epidemic of staphylococcal skin abscesses. Pediatrics 2010; 125:e618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43831/abstract/4\">",
"      Sosin DM, Gunn RA, Ford WL, Skaggs JW. An outbreak of furunculosis among high school athletes. Am J Sports Med 1989; 17:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43831/abstract/5\">",
"      Zimakoff J, Rosdahl VT, Petersen W, Scheibel J. Recurrent staphylococcal furunculosis in families. Scand J Infect Dis 1988; 20:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43831/abstract/6\">",
"      Gira AK, Reisenauer AH, Hammock L, et al. Furunculosis due to Mycobacterium mageritense associated with footbaths at a nail salon. J Clin Microbiol 2004; 42:1813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43831/abstract/7\">",
"      Vugia DJ, Jang Y, Zizek C, et al. Mycobacteria in nail salon whirlpool footbaths, California. Emerg Infect Dis 2005; 11:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43831/abstract/8\">",
"      Kars M, van Dijk H, Salimans MM, et al. Association of furunculosis and familial deficiency of mannose-binding lectin. Eur J Clin Invest 2005; 35:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43831/abstract/9\">",
"      Gordon RJ, Lowy FD. Bacterial infections in drug users. N Engl J Med 2005; 353:1945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43831/abstract/10\">",
"      Binswanger IA, Kral AH, Bluthenthal RN, et al. High prevalence of abscesses and cellulitis among community-recruited injection drug users in San Francisco. Clin Infect Dis 2000; 30:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43831/abstract/11\">",
"      Begier EM, Frenette K, Barrett NL, et al. A high-morbidity outbreak of methicillin-resistant Staphylococcus aureus among players on a college football team, facilitated by cosmetic body shaving and turf burns. Clin Infect Dis 2004; 39:1446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43831/abstract/12\">",
"      Summanen PH, Talan DA, Strong C, et al. Bacteriology of skin and soft-tissue infections: comparison of infections in intravenous drug users and individuals with no history of intravenous drug use. Clin Infect Dis 1995; 20 Suppl 2:S279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43831/abstract/13\">",
"      Squire BT, Fox JC, Anderson C. ABSCESS: applied bedside sonography for convenient evaluation of superficial soft tissue infections. Acad Emerg Med 2005; 12:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43831/abstract/14\">",
"      Naimi TS, LeDell KH, Como-Sabetti K, et al. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 2003; 290:2976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43831/abstract/15\">",
"      Baggett HC, Hennessy TW, Rudolph K, et al. Community-onset methicillin-resistant Staphylococcus aureus associated with antibiotic use and the cytotoxin Panton-Valentine leukocidin during a furunculosis outbreak in rural Alaska. J Infect Dis 2004; 189:1565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43831/abstract/16\">",
"      Meislin HW, Lerner SA, Graves MH, et al. Cutaneous abscesses. Anaerobic and aerobic bacteriology and outpatient management. Ann Intern Med 1977; 87:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43831/abstract/17\">",
"      Ghoneim AT, McGoldrick J, Blick PW, et al. Aerobic and anaerobic bacteriology of subcutaneous abscesses. Br J Surg 1981; 68:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43831/abstract/18\">",
"      Brook I, Frazier EH. Aerobic and anaerobic bacteriology of wounds and cutaneous abscesses. Arch Surg 1990; 125:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43831/abstract/19\">",
"      Rajendran PM, Young D, Maurer T, et al. Randomized, double-blind, placebo-controlled trial of cephalexin for treatment of uncomplicated skin abscesses in a population at risk for community-acquired methicillin-resistant Staphylococcus aureus infection. Antimicrob Agents Chemother 2007; 51:4044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43831/abstract/20\">",
"      Ruhe JJ, Smith N, Bradsher RW, Menon A. Community-onset methicillin-resistant Staphylococcus aureus skin and soft-tissue infections: impact of antimicrobial therapy on outcome. Clin Infect Dis 2007; 44:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43831/abstract/21\">",
"      Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006; 355:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43831/abstract/22\">",
"      Demos M, McLeod MP, Nouri K. Recurrent furunculosis: a review of the literature. Br J Dermatol 2012; 167:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43831/abstract/23\">",
"      Miller LG, Quan C, Shay A, et al. A prospective investigation of outcomes after hospital discharge for endemic, community-acquired methicillin-resistant and -susceptible Staphylococcus aureus skin infection. Clin Infect Dis 2007; 44:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43831/abstract/24\">",
"      Bobrow BJ, Pollack CV Jr, Gamble S, Seligson RA. Incision and drainage of cutaneous abscesses is not associated with bacteremia in afebrile adults. Ann Emerg Med 1997; 29:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43831/abstract/25\">",
"      Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 2007; 116:1736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43831/abstract/26\">",
"      Gorwitz RJ. The role of ancillary antimicrobial therapy for treatment of uncomplicated skin infections in the era of community-associated methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2007; 44:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43831/abstract/27\">",
"      Llera JL, Levy RC. Treatment of cutaneous abscess: a double-blind clinical study. Ann Emerg Med 1985; 14:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43831/abstract/28\">",
"      Macfie J, Harvey J. The treatment of acute superficial abscesses: a prospective clinical trial. Br J Surg 1977; 64:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43831/abstract/29\">",
"      Fridkin SK, Hageman JC, Morrison M, et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med 2005; 352:1436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43831/abstract/30\">",
"      Paydar KZ, Hansen SL, Charlebois ED, et al. Inappropriate antibiotic use in soft tissue infections. Arch Surg 2006; 141:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43831/abstract/31\">",
"      Duong M, Markwell S, Peter J, Barenkamp S. Randomized, controlled trial of antibiotics in the management of community-acquired skin abscesses in the pediatric patient. Ann Emerg Med 2010; 55:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43831/abstract/32\">",
"      Davis SL, Perri MB, Donabedian SM, et al. Epidemiology and outcomes of community-associated methicillin-resistant Staphylococcus aureus infection. J Clin Microbiol 2007; 45:1705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43831/abstract/33\">",
"      Schmitz GR, Bruner D, Pitotti R, et al. Randomized controlled trial of trimethoprim-sulfamethoxazole for uncomplicated skin abscesses in patients at risk for community-associated methicillin-resistant Staphylococcus aureus infection. Ann Emerg Med 2010; 56:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43831/abstract/34\">",
"      Duong M, Markwell S, Peter J, Barenkamp S. Randomized, controlled trial of antibiotics in the management of community-acquired skin abscesses in the pediatric patient. Ann Emerg Med 2010; 55:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43831/abstract/35\">",
"      Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7656 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.25.216.6-A93D27A9D4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_51_43831=[""].join("\n");
var outline_f42_51_43831=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Skin abscesses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Furuncles and carbuncles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Incision and drainage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Role of antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Antibiotic selection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      RECURRENT INFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/7656\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7656|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?40/19/41279\" title=\"figure 1\">",
"      Central triangle of the face",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7656|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?19/51/20287\" title=\"picture 1\">",
"      Skin abscess",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?35/13/36048\" title=\"picture 2\">",
"      Carbuncle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7656|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?39/12/40139\" title=\"table 1\">",
"      Parenteral antibiotics for infections due to MRSA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/57/10140\" title=\"table 2\">",
"      Oral antibiotics for infections due to MRSA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/60/3020\" title=\"table 3\">",
"      Rx MRSA skin infections in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?5/9/5275\" title=\"table 4\">",
"      Risk factors for MRSA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/21/7517\" title=\"table 5\">",
"      Empiric therapy gram negatives and anaerobes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/36/585?source=related_link\">",
"      Antimicrobial prophylaxis for bacterial endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/26/43433?source=related_link\">",
"      Approach to the adult with recurrent infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/47/30458?source=related_link\">",
"      Approach to the child with recurrent infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/37/33365?source=related_link\">",
"      Botryomycosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/11/12469?source=related_link\">",
"      Clinical features and diagnosis of sporotrichosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis?source=related_link\">",
"      Clinical manifestations and diagnosis of cutaneous leishmaniasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/10/30888?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of tularemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/53/20313?source=related_link\">",
"      Complications, diagnosis, and treatment of odontogenic infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/55/20345?source=related_link\">",
"      Diagnostic assays for HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/54/22375?source=related_link\">",
"      Disorders of Bartholin gland",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/21/30042?source=related_link\">",
"      Epidemiology and clinical spectrum of methicillin-resistant Staphylococcus aureus infections in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/53/8026?source=related_link\">",
"      Epidemiology of methicillin-resistant Staphylococcus aureus infection in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/32/33290?source=related_link\">",
"      Evaluation and management of suspected methicillin-resistant Staphylococcus aureus skin and soft tissue infections in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/55/22387?source=related_link\">",
"      Folliculitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/34/42537?source=related_link\">",
"      Infectious causes of fever and rash in non-HIV immunocompromised hosts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/4/79?source=related_link\">",
"      Mycology, pathogenesis, and epidemiology of blastomycosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/7/6265?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of hidradenitis suppurativa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/63/20465?source=related_link\">",
"      Patient information: Boil (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/40/26246?source=related_link\">",
"      Perianal abscess: Clinical manifestations, diagnosis, treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/59/17338?source=related_link\">",
"      Prevention and control of methicillin-resistant Staphylococcus aureus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/25/5530?source=related_link\">",
"      Rapidly growing mycobacterial infections in HIV-negative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/16/2312?source=related_link\">",
"      Screening for diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/38/23145?source=related_link\">",
"      Septic dural sinus thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/43/20152?source=related_link\">",
"      Skin lesions in the returning traveler",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/46/5865?source=related_link\">",
"      Technique of incision and drainage for skin abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/6/29802?source=related_link\">",
"      Treatment of invasive methicillin-resistant Staphylococcus aureus infection in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/48/21258?source=related_link\">",
"      Treatment of invasive methicillin-resistant Staphylococcus aureus infections in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/7/4216?source=related_link\">",
"      Treatment of skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_51_43832="Hydrocodone and acetaminophen: Drug information";
var content_f42_51_43832=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Hydrocodone and acetaminophen: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?22/53/23381?source=see_link\">",
"    see \"Hydrocodone and acetaminophen: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/34/22055?source=see_link\">",
"    see \"Hydrocodone and acetaminophen: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F13135478\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F179839\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      hycet&reg;;",
"     </li>",
"     <li>",
"      Lorcet&reg; 10/650;",
"     </li>",
"     <li>",
"      Lorcet&reg; Plus;",
"     </li>",
"     <li>",
"      Lortab&reg;;",
"     </li>",
"     <li>",
"      Margesic&reg; H;",
"     </li>",
"     <li>",
"      Maxidone&reg;;",
"     </li>",
"     <li>",
"      Norco&reg;;",
"     </li>",
"     <li>",
"      Stagesic&trade;;",
"     </li>",
"     <li>",
"      Vicodin ES&reg;;",
"     </li>",
"     <li>",
"      Vicodin HP&reg;;",
"     </li>",
"     <li>",
"      Vicodin&reg;;",
"     </li>",
"     <li>",
"      Xodol&reg; 10/300;",
"     </li>",
"     <li>",
"      Xodol&reg; 5/300;",
"     </li>",
"     <li>",
"      Xodol&reg; 7.5/300;",
"     </li>",
"     <li>",
"      Zamicet&trade;;",
"     </li>",
"     <li>",
"      Zolvit&reg;;",
"     </li>",
"     <li>",
"      Zydone&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F179856\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Analgesic Combination (Opioid)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F179841\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Pain management (analgesic):",
"     </b>",
"     Oral (doses should be titrated to appropriate analgesic effect): Average starting dose in opioid naive patients: Hydrocodone 5-10 mg 4 times/day; the dosage of acetaminophen should be limited to &le;4 g/day (and possibly less in patients with hepatic impairment or ethanol use).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <i>",
"      Dosage ranges (based on specific product labeling):",
"     </i>",
"     Hydrocodone 2.5-10 mg every 4-6 hours (maximum dose of hydrocodone may be limited by the acetaminophen content of specific product)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F179850\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/34/22055?source=see_link\">",
"      see \"Hydrocodone and acetaminophen: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     <b>",
"      Pain management (analgesic):",
"     </b>",
"     Oral (doses should be titrated to appropriate analgesic effect):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children 2-13 years or &lt;50 kg: Hydrocodone 0.1-0.2 mg/kg/dose every 4-6 hours; do not exceed 6 doses/day or the maximum recommended dose of acetaminophen",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;50 kg: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F179842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Doses should be titrated to appropriate analgesic effect; 2.5-5 mg of the hydrocodone component every 4-6 hours. Do not exceed 4 g/day of acetaminophen.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15897560\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F179843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution. Limited, low-dose therapy usually well tolerated in hepatic disease/cirrhosis; however, cases of hepatotoxicity at daily acetaminophen dosages &lt;4 g/day have been reported. Avoid chronic use in hepatic impairment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F179820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Margesic&reg; H, Stagesic&trade;: Hydrocodone bitartrate 5 mg and acetaminophen 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elixir, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lortab&reg;: Hydrocodone bitartrate 7.5 mg and acetaminophen 500 mg per 15 mL (480 mL) [contains ethanol 7%, propylene glycol; tropical fruit punch flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral: Hydrocodone bitartrate 7.5 mg and acetaminophen 325 mg per 15 mL;  hydrocodone bitartrate 7.5 mg and acetaminophen 500 mg per 15 mL (5 mL, 10 mL, 15 mL, 118 mL, 473 mL); hydrocodone bitartrate 10 mg and acetaminophen 325 mg per 15 mL (7.5 mL, 15 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     hycet&reg;: Hydrocodone bitartrate 7.5 mg and acetaminophen 325 mg per 15 mL (473 mL) [contains ethanol 7%, propylene glycol; tropical fruit punch flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zamicet&trade;: Hydrocodone bitartrate 10 mg and acetaminophen 325 mg per 15 mL (473 mL) [contains ethanol 6.7%, propylene glycol; fruit flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zolvit&reg;: Hydrocodone bitartrate 10 mg and acetaminophen 300 mg per 15 mL (480 mL) [contains ethanol 7%, propylene glycol; tropical fruit punch flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hydrocodone bitartrate 2.5 mg and acetaminophen 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hydrocodone bitartrate 5 mg and acetaminophen 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hydrocodone bitartrate 5 mg and acetaminophen 325 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hydrocodone bitartrate 5 mg and acetaminophen 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hydrocodone bitartrate 7.5 mg and acetaminophen 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hydrocodone bitartrate 7.5 mg and acetaminophen 325 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hydrocodone bitartrate 7.5 mg and acetaminophen 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hydrocodone bitartrate 7.5 mg and acetaminophen 650 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hydrocodone bitartrate 7.5 mg and acetaminophen 750 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hydrocodone bitartrate 10 mg and acetaminophen 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hydrocodone bitartrate 10 mg and acetaminophen 325 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hydrocodone bitartrate 10 mg and acetaminophen 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hydrocodone bitartrate 10 mg and acetaminophen 650 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hydrocodone bitartrate 10 mg and acetaminophen 660 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hydrocodone bitartrate 10 mg and acetaminophen 750 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lorcet&reg; 10/650: Hydrocodone bitartrate 10 mg and acetaminophen 650 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lorcet&reg; Plus: Hydrocodone bitartrate 7.5 mg and acetaminophen 650 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lortab&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     5/500: Hydrocodone bitartrate 5 mg and acetaminophen 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     7.5/500: Hydrocodone bitartrate 7.5 mg and acetaminophen 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     10/500: Hydrocodone bitartrate 10 mg and acetaminophen 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maxidone&reg;: Hydrocodone bitartrate 10 mg and acetaminophen 750 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Norco&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Hydrocodone bitartrate 5 mg and acetaminophen 325 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Hydrocodone bitartrate 7.5 mg and acetaminophen 325 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Hydrocodone bitartrate 10 mg and acetaminophen 325 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vicodin&reg;: Hydrocodone bitartrate 5 mg and acetaminophen 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vicodin ES&reg;: Hydrocodone bitartrate 7.5 mg and acetaminophen 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vicodin HP&reg;: Hydrocodone bitartrate 10 mg and acetaminophen 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Xodol&reg;:",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:4em;text-align:justify;\">",
"     5/300: Hydrocodone bitartrate 5 mg and acetaminophen 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     7.5/300: Hydrocodone bitartrate 7.5 mg and acetaminophen 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     10/300: Hydrocodone bitartrate 10 mg and acetaminophen 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zydone&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Hydrocodone bitartrate 5 mg and acetaminophen 400 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Hydrocodone bitartrate 7.5 mg and acetaminophen 400 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Hydrocodone bitartrate 10 mg and acetaminophen 400 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F179805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Oral solution, tablet",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F179858\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-III",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F179823\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relief of moderate-to-severe pain",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F179867\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Lorcet&reg; may be confused with Fioricet&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Lortab&reg; may be confused with Cortef&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Vicodin&reg; may be confused with Hycodan, Indocin&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Zydone&reg; may be confused with Vytone",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Duplicate therapy issues: This product contains acetaminophen, which may be a component of other combination products. Do not exceed the maximum recommended daily dose of acetaminophen.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F179854\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Bradycardia, cardiac arrest, circulatory collapse, coma, hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, dizziness, drowsiness, dysphoria, euphoria, fear, lethargy, lightheadedness, malaise, mental clouding, mental impairment, mood changes, physiological dependence, sedation, somnolence, stupor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypoglycemic coma",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, constipation, gastric distress, heartburn, nausea, peptic ulcer, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Ureteral spasm, urinary retention, vesical sphincter spasm",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, bleeding time prolonged, hemolytic anemia, iron deficiency anemia, occult blood loss, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Hepatic necrosis, hepatitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Skeletal muscle rigidity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Hearing impairment or loss (chronic overdose)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Renal toxicity, renal tubular necrosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Acute airway obstruction, apnea, dyspnea, respiratory depression (dose related)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reactions, clamminess, diaphoresis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F179826\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to hydrocodone, acetaminophen, or any component of the formulation; CNS depression; severe respiratory depression",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F179809\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity:",
"     <b>",
"      [U.S. Boxed Warning]: Acetaminophen may cause severe hepatotoxicity, potentially requiring liver transplant or resulting in death; hepatotoxicity is usually associated with excessive acetaminophen intake (&gt;4 g/day).",
"     </b>",
"     Risk is increased with alcohol use, pre-existing liver disease, and intake of more than one source of acetaminophen-containing medications. Chronic daily dosing in adults has also resulted in liver damage in some patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity/anaphylactic reactions: Hypersensitivity and anaphylactic reactions have been reported with acetaminophen use; discontinue immediately if symptoms of allergic or hypersensitivity reactions occur. Use with caution in patients with hypersensitivity reactions to other phenanthrene derivative opioid agonists (codeine, hydromorphone, levorphanol, oxycodone, oxymorphone).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension: May cause hypotension; use with caution in patients with hypovolemia, cardiovascular disease (including acute MI), or drugs which may exaggerate hypotensive effects (including phenothiazines or general anesthetics).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abdominal conditions: Hydrocodone may obscure diagnosis or clinical course of patients with acute abdominal conditions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenocortical insufficiency: Use with caution in patients with adrenocortical insufficiency, including Addison's disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Biliary tract impairment: Use with caution in patients with biliary tract dysfunction; acute pancreatitis may cause constriction of sphincter of Oddi.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug abuse: Use hydrocodone with caution in patients with a history of drug abuse or acute alcoholism; potential for drug dependency exists. Tolerance, psychological and physical dependence may occur with prolonged use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ethanol use: Use with caution in patients with alcoholic liver disease; consuming &ge;3 alcoholic drinks/day may increase the risk of liver damage.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; G6PD deficiency: Use with caution in patients with known G6PD deficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Head trauma: Use with extreme caution in patients with head injury, intracranial lesions, or elevated intracranial pressure; exaggerated elevation of ICP may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Obesity: Use with caution in patients who are morbidly obese.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostatic hyperplasia/urinary stricture: Use hydrocodone with caution in patients with prostatic hyperplasia and/or urinary stricture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psychosis: Use with caution in patients with toxic psychosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use hydrocodone with caution in patients with pre-existing respiratory compromise (hypoxia and/or hypercapnia), COPD or other obstructive pulmonary disease, and kyphoscoliosis or other skeletal disorder which may alter respiratory function; critical respiratory depression may occur, even at therapeutic dosages. May suppress cough reflex; use with caution postoperatively and in patients with pulmonary disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizures: Use with caution in patients with a history of seizure disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CYP2D6 &ldquo;poor metabolizers&rdquo;: Due to the role of CYP2D6 in the metabolism of hydrocodone to hydromorphone (an active metabolite with higher binding affinity to mu-opioid receptors compared to hydrocodone), patients with genetic variations of CYP2D6, including &ldquo;poor metabolizers&rdquo; or &ldquo;extensive metabolizers,&rdquo; may have decreased or increased hydromorphone formation, respectively. Variable effects in positive and negative opioid effects have been reported in these patients; however, limited data exists to determine if clinically significant differences of analgesia and toxicity can be predicted based on CYP2D6 phenotype (Hutchinson, 2004; Otton, 1993; Zhou, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Debilitated patients: Use with caution in debilitated patients; there is a greater potential for critical respiratory depression, even at therapeutic dosages.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; may be more sensitive to adverse effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dosage limit: Limit acetaminophen dose from all sources (prescription and OTC) to &lt;4 g/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal: Concurrent use of agonist/antagonist analgesics may precipitate withdrawal symptoms and/or reduced analgesic efficacy in patients following prolonged therapy with mu opioid agonists. Abrupt discontinuation following prolonged use may also lead to withdrawal symptoms.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F179851\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F179814\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alvimopan: Analgesics (Opioid) may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation.  Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May increase the excretion of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May enhance the analgesic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticonvulsants (Hydantoin): May increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Busulfan: Acetaminophen may increase the serum concentration of Busulfan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cholestyramine Resin: May decrease the absorption of Acetaminophen. Effect is minimal if cholestyramine is administered 1 hour after acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: Acetaminophen may enhance the hepatotoxic effect of Dasatinib. Dasatinib may increase the serum concentration of Acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: Acetaminophen may enhance the hepatotoxic effect of Imatinib. Imatinib may increase the serum concentration of Acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: May enhance the adverse/toxic effect of Acetaminophen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrapone: May increase the serum concentration of Acetaminophen. More importantly, by inhibiting the conjugative metabolism of acetaminophen, metyrapone may shift the metabolism towards the oxidative route that produces a hepatotoxic metabolite.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mipomersen: Acetaminophen may enhance the hepatotoxic effect of Mipomersen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mixed Agonist / Antagonist Opioids: May diminish the analgesic effect of Analgesics (Opioid). Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Acetaminophen. Probenecid may also limit the formation of at least one major non-toxic metabolite, possibly increasing the potential for formation of the toxic NAPQI metabolite.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May decrease serum concentrations of the active metabolite(s) of Hydrocodone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: Analgesics (Opioid) may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: Acetaminophen may enhance the hepatotoxic effect of SORAfenib. SORAfenib may increase the serum concentration of Acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Succinylcholine: May enhance the bradycardic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Analgesics (Opioid) may enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Acetaminophen may enhance the anticoagulant effect of Vitamin K Antagonists. Most likely with daily acetaminophen doses &gt;1.3 g for &gt;1 week.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F179836\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Consuming &ge;3 alcoholic drinks/day may increase the risk of liver damage. Ethanol may also increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid valerian, St John's wort, SAMe, kava kava (may increase risk of excessive sedation).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F179815\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F179829\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hydrocodone is teratogenic in animal reproduction studies. In humans, birth defects, including some heart defects, have been associated with maternal use of opioid analgesics, including hydrocodone, during the first trimester of pregnancy (Broussard, 2011). Use of opioids during pregnancy may produce physical dependence in the neonate. Symptoms of opioid withdrawal may include excessive crying, diarrhea, fever, hyper-reflexia, irritability, respiratory rate increased, sneezing, tremors, vomiting, or yawning; respiratory depression may occur in the newborn if opioids are used prior to delivery. Also refer to acetaminophen monograph.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F179845\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F179830\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acetaminophen and hydrocodone are excreted in breast milk. In one study (n=30), the calculated dose of hydrocodone to a nursing infant was 0.2% to 9% (mean: 2.4%) of the weight-adjusted maternal dose. Hydromorphone was also measurable in 12 cases; the total opioid dose to a nursing infant was calculated to be 0.1% to 9.9% (mean: 1.5%) of the weight-adjusted maternal dose. Concentrations may be increased in women who are extensive metabolizers of CYP2D6. Caution should be used since most persons are not aware of their CYP2D6 genotype status. When hydrocodone is used in breast-feeding women, it is recommended to use the lowest dose for the shortest duration of time and observe the infant for adverse events. Some clinicians recommend limiting the dose to hydrocodone bitartrate 30 mg/day (Sauberan, 2011). The manufacturers recommend discontinuing the medication or to discontinue nursing during therapy. Also refer to acetaminophen monograph.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F179828\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Hydrogesic Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-500 mg (100): $25.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Elixir",
"     </b>",
"     (Lortab Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5-500 mg/15 mL (473 mL): $220.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Hycet Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5-325 mg/15 mL (473 mL): $227.77",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Hydrocodone-Acetaminophen Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5-325 mg/15 mL (473 mL): $139.77",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5-500 mg/15 mL (473 mL): $58.12",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Liquicet Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-500 mg/15 mL (473 mL): $201.03",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Zamicet Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-325 mg/15 mL (473 mL): $173.12",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Zolvit Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-300 mg/15 mL (473 mL): $92.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Co-Gesic Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-500 mg (100): $137.58",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Hydrocodone-Acetaminophen Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5-325 mg (100): $323.76",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5-500 mg (100): $30.30",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-300 mg (100): $191.04",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-325 mg (100): $54.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-500 mg (100): $44.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5-300 mg (100): $214.27",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5-325 mg (100): $61.83",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5-500 mg (100): $50.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5-650 mg (100): $69.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5-750 mg (100): $43.78",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-300 mg (100): $276.44",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-325 mg (100): $70.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-500 mg (100): $53.27",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-650 mg (100): $97.76",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-660 mg (100): $61.17",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-750 mg (100): $111.55",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Lorcet 10/650 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-650 mg (100): $183.54",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Lorcet Plus Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5-650 mg (100): $130.45",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Lortab Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-500 mg (100): $200.10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5-500 mg (100): $221.66",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-500 mg (100): $232.38",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Norco Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-325 mg (100): $171.62",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-325 mg (100): $275.26",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Vicodin ES Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5-300 mg (100): $216.43",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Vicodin HP Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-300 mg (100): $279.23",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Vicodin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-300 mg (100): $197.68",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Xodol Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-300 mg (100): $716.11",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5-300 mg (100): $716.11",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-300 mg (100): $716.11",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Zydone Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-400 mg (100): $69.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5-400 mg (100): $77.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-400 mg (100): $93.92",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F179817\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pain relief, respiratory and mental status, blood pressure",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F179808\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hydrocodone, as with other narcotic (opiate) analgesics, blocks pain perception in the cerebral cortex by binding to specific receptor molecules (opiate receptors) within the neuronal membranes of synapses. This binding results in a decreased synaptic chemical transmission throughout the CNS thus inhibiting the flow of pain sensations into the higher centers. Mu and kappa are the two subtypes of the opiate receptor which hydrocodone binds to cause analgesia.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Acetaminophen inhibits the synthesis of prostaglandins in the CNS and peripherally blocks pain impulse generation; produces antipyresis from inhibition of hypothalamic heat-regulating center.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F179825\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acetaminophen:",
"     </b>",
"     See Acetaminophen monograph.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hydrocodone:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Onset of action: Narcotic analgesic: 10-20 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Duration: 4-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Metabolism: Hepatic; O-demethylation via primarily CYP2D6 to hydromorphone (major, active metabolite with ~10- to 33-fold higher or as much as a &gt;100-fold higher binding affinity for the mu-opioid receptor than hydrocodone); N-demethylation via CYP3A4 to norhydrocodone (major metabolite); and ~40% of metabolism/clearance occurs via other non-CYP pathways, including 6-ketosteroid reduction to 6-alpha-hydrocol and 6-beta-hydrocol, and other elimination pathways (eg, fecal, biliary, intestinal, renal) (Hutchinson, 2004; Volpe, 2011; Zhou, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Half-life elimination: 3.3-4.4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Excretion: Urine (26% of single dose in 72 hours, with ~12% as unchanged drug, 5% as norhydrocodone, 4% as conjugated hydrocodone, 3% as 6-hydrocodol, and 0.21% as conjugated 6-hydromorphol (Zhou, 2009)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Acute Pain Management in Infants, Children, and Adolescents: Operative or Medical Procedures and Trauma (Quick Reference Guide for Clinicians),&rdquo; Rockville, MD: U.S. Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research. AHCPR Publication No. 92-0020. February 1992.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;American Academy of Pediatrics Committee on Drugs. The Transfer of Drugs and Other Chemicals Into Human Milk,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/51/43832/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anderson PO, Sauberan JB, Lane JR, et al, &ldquo;Hydrocodone Excretion Into Breast Milk: The First Two Reported Cases,&rdquo;",
"      <i>",
"       Breastfeed Med",
"      </i>",
"      , 2007, 2(1):10-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/51/43832/abstract-text/17661614/pubmed\" id=\"17661614\" target=\"_blank\">",
"        17661614",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antlitz AM, Mead JA Jr, and Tolentino MA, &ldquo;Potentiation of Oral Anticoagulant Therapy by Acetaminophen,&rdquo;",
"      <i>",
"       Curr Ther Res Clin Exp",
"      </i>",
"      , 1968, 10(10):501-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/51/43832/abstract-text/4971464/pubmed\" id=\"4971464\" target=\"_blank\">",
"        4971464",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bagheri H, Bernhard NB, and Montastruc JL, &ldquo;Potentiation of the Acenocoumarol Anticoagulant Effect by Acetaminophen,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1999, 33(4):506.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/51/43832/abstract-text/10332548/pubmed\" id=\"10332548\" target=\"_blank\">",
"        10332548",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bartle WR and Blakely JA, &ldquo;Potentiation of Warfarin Anticoagulation by Acetaminophen,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1991, 265(10):1260.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/51/43832/abstract-text/1995971/pubmed\" id=\"1995971\" target=\"_blank\">",
"        1995971",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bean-Lijewski JD, Kruitbosch SH, Hutchinson L, et al, &ldquo;Post-Tonsillectomy Pain Management in Children: Can We Do Better?&rdquo;",
"      <i>",
"       Otolaryngol Head Neck Surg",
"      </i>",
"      , 2007, 137(4):545-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/51/43832/abstract-text/17903568/pubmed\" id=\"17903568\" target=\"_blank\">",
"        17903568",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boeijinga JJ, Boerstra EE, Ris P, et al, &ldquo;Interaction Between Paracetamol and Coumarin Anticoagulants,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1982, 1(8270):506.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/51/43832/abstract-text/6121161/pubmed\" id=\"6121161\" target=\"_blank\">",
"        6121161",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Broussard CS, Rasmussen SA, Reefhuis J, et al, \"National Birth Defects Prevention Study: Maternal Treatment With Opioid Analgesics and Risk for Birth Defects,\"",
"      <i>",
"       Am J Obstet Gynecol",
"      </i>",
"      , 2011, 204(4):314.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/51/43832/abstract-text/21345403/pubmed\" id=\"21345403\" target=\"_blank\">",
"        21345403",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Carpenter, RL, &ldquo;Optimizing Postoperative Pain Management,&rdquo;",
"      <i>",
"       Am Fam Physician",
"      </i>",
"      , 1997, 56(3):835-44, 847-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/51/43832/abstract-text/9301576/pubmed\" id=\"9301576\" target=\"_blank\">",
"        9301576",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dionne RA, &ldquo;New Approaches to Preventing and Treating Postoperative Pain,&rdquo;",
"      <i>",
"       J Am Dent Assoc",
"      </i>",
"      , 1992, 123(6):26-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/51/43832/abstract-text/1619142/pubmed\" id=\"1619142\" target=\"_blank\">",
"        1619142",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gadisseur AP, Van Der Meer FJ, and Rosendaal FR, &ldquo;Sustained Intake of Paracetamol (Acetaminophen) During Oral Anticoagulant Therapy With Coumarins Does Not Cause Clinically Important INR Changes: A Randomized Double-Blind Clinical Trial,&rdquo;",
"      <i>",
"       J Thromb Haemost",
"      </i>",
"      , 2003, 1(4):714-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/51/43832/abstract-text/12871405/pubmed\" id=\"12871405\" target=\"_blank\">",
"        12871405",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gebauer MG, Nyfort-Hansen K, Henschke PJ, et al, &ldquo;Warfarin and Acetaminophen Interaction,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2003, 23(1):109-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/51/43832/abstract-text/12523469/pubmed\" id=\"12523469\" target=\"_blank\">",
"        12523469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gobetti JP, &ldquo;Controlling Dental Pain,&rdquo;",
"      <i>",
"       J Am Dent Assoc",
"      </i>",
"      , 1992, 123(6):47-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/51/43832/abstract-text/1619145/pubmed\" id=\"1619145\" target=\"_blank\">",
"        1619145",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hutchinson MR, Menelaou A, Foster DJ, et al, &ldquo;CYP2D6 and CYP3A4 Involvement in the Primary Oxidative Metabolism of Hydrocodone by Human Liver Microsomes,&rdquo;",
"      <i>",
"       Br J Clin Pharmacol",
"      </i>",
"      , 2004, 57(3):287-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/51/43832/abstract-text/14998425/pubmed\" id=\"14998425\" target=\"_blank\">",
"        14998425",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hylek EM, Heiman H, Skates SJ, et al, &ldquo;Acetaminophen and Other Risk Factors for Excessive Warfarin Anticoagulation,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1998, 279(9):657-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/51/43832/abstract-text/9496982/pubmed\" id=\"9496982\" target=\"_blank\">",
"        9496982",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kwan D, Bartle WR, and Walker SE, &ldquo;The Effects of Acute and Chronic Acetaminophen Dosing on the Pharmacodynamics and Pharmacokinetics of (R)- and (S)-Warfarin,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1995, 57:212.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mokhlesi B, Leikin JB, Murray P, et al, &ldquo;Adult Toxicology in Critical Care: Part II: Specific Poisonings,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2003, 123(3):897-922.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/51/43832/abstract-text/12628894/pubmed\" id=\"12628894\" target=\"_blank\">",
"        12628894",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Molina DK and Hargrove VM, &ldquo;What Is the Lethal Concentration of Hydrocodone?&rdquo;",
"      <i>",
"       Am J Forensic Med Pathol",
"      </i>",
"      , 2011, 32(2):108-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/51/43832/abstract-text/20407360/pubmed\" id=\"20407360\" target=\"_blank\">",
"        20407360",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Otton SV, Schadel M, Cheung SW, et al, &ldquo;CYP2D6 Phenotype Determines the Metabolic Conversion of Hydrocodone to Hydromorphone,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1993, 54(5):463-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/51/43832/abstract-text/7693389/pubmed\" id=\"7693389\" target=\"_blank\">",
"        7693389",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain,&rdquo; 6th ed, Glenview, IL: American Pain Society, 2008.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rathmell JP, Viscomi CM, and Ashburn MA, &ldquo;Management of Nonobstetric Pain During Pregnancy and Lactation,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 1997, 85(5):1074-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/51/43832/abstract-text/9356103/pubmed\" id=\"9356103\" target=\"_blank\">",
"        9356103",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rubin RN, Mentzer RL, and Budzynski AZ, &ldquo;Potentiation of Anticoagulant Effect of Warfarin by Acetaminophen (Tylenol&reg;),&rdquo;",
"      <i>",
"       Clin Res",
"      </i>",
"      , 1984, 32:698a.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sauberan JB, Anderson PO, Lane JR, et al, \"Breast Milk Hydrocodone and Hydromorphone Levels in Mothers Using Hydrocodone for Postpartum Pain,\"",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2011, 117(3):611-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/51/43832/abstract-text/21343764/pubmed\" id=\"21343764\" target=\"_blank\">",
"        21343764",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tobias JD, &ldquo;Weak Analgesics and Nonsteroidal Anti-Inflammatory Agents in the Management of Children with Acute Pain,&rdquo;",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 2000, 47(3):527-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/51/43832/abstract-text/10835989/pubmed\" id=\"10835989\" target=\"_blank\">",
"        10835989",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van den Bemt PM, Geven LM, Kuitert NA, et al, &ldquo;The Potential Interaction Between Oral Anticoagulants and Acetaminophen in Everyday Practice,&rdquo;",
"      <i>",
"       Pharm World Sci",
"      </i>",
"      , 2002, 24(5):201-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/51/43832/abstract-text/12426965/pubmed\" id=\"12426965\" target=\"_blank\">",
"        12426965",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Volpe DA, McMahon Tobin GA, Mellon RD, et al, &ldquo;Uniform Assessment and Ranking of Opioid Mu Receptor Binding Constants for Selected Opioid Drugs,&rdquo;",
"      <i>",
"       Regul Toxicol Pharmacol",
"      </i>",
"      , 2011, 59(3):385-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/51/43832/abstract-text/21215785 /pubmed\" id=\"21215785 \" target=\"_blank\">",
"        21215785",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zhou SF, &ldquo;Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance: Part II,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 2009, 48(12):761-804.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/51/43832/abstract-text/19902987/pubmed\" id=\"19902987\" target=\"_blank\">",
"        19902987",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8531 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-189.2.19.178-294E67EF58-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_51_43832=[""].join("\n");
var outline_f42_51_43832=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13135478\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179839\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179856\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179841\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179850\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179842\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15897560\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179843\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179820\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179805\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179858\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179823\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179867\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179854\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179826\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179809\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179851\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179814\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179836\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179815\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179829\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179845\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179830\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179828\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179817\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179808\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179825\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8531\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8531|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?22/53/23381?source=related_link\">",
"      Hydrocodone and acetaminophen: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/34/22055?source=related_link\">",
"      Hydrocodone and acetaminophen: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_51_43833="Clinical presentation, classification, and causes of membranoproliferative glomerulonephritis";
var content_f42_51_43833=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical presentation, classification, and causes of membranoproliferative glomerulonephritis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/51/43833/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/51/43833/contributors\">",
"     Fernando C Fervenza, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/51/43833/contributors\">",
"     Sanjeev Sethi, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/51/43833/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/51/43833/contributors\">",
"     Richard J Glassock, MD, MACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/51/43833/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/51/43833/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/51/43833/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1217072877\">",
"    <span class=\"h1\">",
"     INTRODUCTION AND CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Membranoproliferative glomerulonephritis (MPGN) is a pattern of glomerular injury on renal biopsy with characteristic light microscopic changes. The clinical presentation is similar to that in other types of glomerulonephritis. In patients with active disease, the urine sediment reveals hematuria, typically with dysmorphic red cells (",
"    <a class=\"graphic graphic_picture graphicRef79440 \" href=\"mobipreview.htm?24/0/24591\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef62064 \" href=\"mobipreview.htm?13/47/14079\">",
"     picture 2",
"    </a>",
"    ) and occasionally with red cell casts (",
"    <a class=\"graphic graphic_picture graphicRef55778 \" href=\"mobipreview.htm?34/38/35424\">",
"     picture 3",
"    </a>",
"    ); there is a variable degree of proteinuria; and the serum creatinine may be normal or elevated. Occasional patients with indolent disease present late in the course at a time when active inflammation has subsided. Such patients may have a bland urine sediment with a variable degree of proteinuria and elevation in serum creatinine. The diagnosis is made by renal biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43833/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/31/27130?source=see_link\">",
"     \"Differential diagnosis and evaluation of glomerular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/59/34746?source=see_link&amp;anchor=H10#H10\">",
"     \"Etiology and evaluation of hematuria in adults\", section on 'Glomerular versus nonglomerular bleeding'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As will be described below, there are two major types of MPGN, which are based upon immunofluorescence microscopy: immune complex-mediated and complement-mediated. Hypocomplementemia is common in all types of MPGN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43833/abstract/2-6\">",
"     2-6",
"    </a>",
"    ]. In immune complex-mediated MPGN, complement activation occurs via the classic pathway and is typically manifested by a normal or mildly decreased serum C3 concentration and a low serum C4 concentration. In complement-mediated MPGN, there are usually low serum C3 and normal C4 levels due to activation of the alternate pathway [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43833/abstract/3\">",
"     3",
"    </a>",
"    ]. However, complement-mediated MPGN is not excluded by a normal serum C3 concentration, and it is not unusual to find a normal C3 concentration in adults with dense deposit disease (DDD) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43833/abstract/6\">",
"     6",
"    </a>",
"    ] or C3 glomerulonephritis (C3GN). (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Complement-mediated MPGN'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Among patients who have the different forms of MPGN described below, there are generally no differences in clinical presentation with the possible exception of patients with DDD, which is a form of complement-mediated MPGN that is associated with drusen formation that may be seen on fundoscopic examination and with partial lipodystrophy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/26/3498?source=see_link&amp;anchor=H6#H6\">",
"     \"Dense deposit disease (membranoproliferative glomerulonephritis type II)\", section on 'Extrarenal abnormalities'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will review the pathology and pathogenesis of MPGN, a proposed classification based upon immunofluorescence microscopy, the original classification of MPGN based upon electron microscopy (EM), and the limitations of this approach. The treatments of the different types of MPGN, including recurrent MPGN following renal transplantation, are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/17/13594?source=see_link\">",
"     \"Evaluation and treatment of membranoproliferative glomerulonephritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/26/3498?source=see_link\">",
"     \"Dense deposit disease (membranoproliferative glomerulonephritis type II)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/54/32614?source=see_link\">",
"     \"Membranoproliferative glomerulonephritis: Recurrence after transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     PATHOLOGY AND PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Membranoproliferative glomerulonephritis (MPGN), also known as mesangiocapillary glomerulonephritis, is a pattern of glomerular injury on light microscopy that is characterized by mesangial hypercellularity, endocapillary proliferation, and double-contour formation along the glomerular capillary walls (",
"    <a class=\"graphic graphic_picture graphicRef67999 graphicRef78967 \" href=\"mobipreview.htm?39/57/40858\">",
"     picture 4A-B",
"    </a>",
"    ). The term \"MPGN\" is derived from the two characteristic histologic changes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thickened glomerular basement membrane (GBM) due to deposition of immune complexes",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      complement factors, interposition of the mesangial cell and other cellular elements between the GBM and the endothelial cell, and new basement membrane formation.",
"     </li>",
"     <li>",
"      Increased mesangial and endocapillary cellularity, often leading to a lobular appearance of the glomerular tuft. The increase in cellularity results from both proliferation of mesangial cells and influx of circulating monocytes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Two primary mechanisms have been described in the pathogenesis of MPGN:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immune complex deposition leading to activation of complement (immune complex-mediated) (see",
"      <a class=\"local\" href=\"#H455985606\">",
"       'Immune complex-mediated MPGN'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Dysregulation and persistent activation of the alternative complement pathway (complement-mediated) (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Complement-mediated MPGN'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H981933439\">",
"    <span class=\"h1\">",
"     CLASSIFICATION BASED UPON IMMUNOFLUORESCENCE MICROSCOPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Membranoproliferative glomerulonephritis (MPGN) has traditionally been classified as MPGN types I, II, and III based upon electron microscopic findings. However, advances in the understanding of processes involved in the pathogenesis of MPGN suggest that the electron microscopy-based classification can result in overlap among the types (",
"    <a class=\"graphic graphic_algorithm graphicRef86556 \" href=\"mobipreview.htm?37/58/38830\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43833/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H559999613\">",
"     'Classification based upon electron microscopy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In contrast, a classification that is based upon the pathogenetic process helps to direct the clinical evaluation and to provide disease-specific treatments. In this system, MPGN is classified as being mediated by immune complexes, by complement dysregulation that leads to persistent activation of the alternative complement pathway, or rarely, by mechanisms not involving immunoglobulin or complement deposition, such as endothelial injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43833/abstract/7\">",
"     7",
"    </a>",
"    ]. These disorders can be distinguished by immunofluorescence microscopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43833/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Immune complex-mediated MPGN is characterized by the presence of immune complexes and complement components, while complement-mediated MPGN is characterized by the presence of complement components in the absence of immune complexes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H455985606\">",
"    <span class=\"h2\">",
"     Immune complex-mediated MPGN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immune complex-mediated MPGN results from chronic antigenemia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    circulating immune complexes and can be seen in chronic infections, autoimmune diseases, and monoclonal gammopathies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43833/abstract/10-18\">",
"     10-18",
"    </a>",
"    ]. An underlying cause can be found in the majority of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43833/abstract/8,9,19\">",
"     8,9,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Immunofluorescence microscopy may suggest the underlying etiology of immune complex-mediated MPGN:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      MPGN resulting from hepatitis C virus infection typically shows granular deposition of IgM, C3, and",
"      <strong>",
"       both",
"      </strong>",
"      kappa and lambda light chains. IgG may or may not be present, and C1q is typically negative. This pattern may also be seen with MPGN induced by other viral infections [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/51/43833/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      MPGN resulting from monoclonal gammopathy is characterized by deposition of monotypic kappa or lambda light chains but not both. MPGN associated with heavy-chain deposition may show immunoglobulin deposition (heavy-chain isotypes) in the absence of either light chain [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/51/43833/abstract/17\">",
"       17",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H455985660\">",
"       'Dysproteinemias'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      MPGN resulting from autoimmune diseases is typically characterized by the \"full house\" pattern of immunoglobulin deposition, including IgG, IgM, IgA, C1q, C3, and kappa and lambda light chains [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/51/43833/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Electron microscopy (EM) in immunoglobulin-positive MPGN typically demonstrates subendothelial and mesangial deposits (",
"    <a class=\"graphic graphic_picture graphicRef64411 \" href=\"mobipreview.htm?8/37/8793\">",
"     picture 5",
"    </a>",
"    ). Subepithelial deposits can also be seen with autoimmune diseases. As an example, patients with diffuse proliferative lupus nephritis can also have membranous lupus with subepithelial deposits (",
"    <a class=\"graphic graphic_picture graphicRef69348 \" href=\"mobipreview.htm?38/39/39543\">",
"     picture 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43833/abstract/2\">",
"     2",
"    </a>",
"    ]. However, EM alone does not differentiate between immune complex-mediated and complement-mediated MPGN.",
"   </p>",
"   <p>",
"    EM may suggest certain underlying diseases. As examples, tubuloreticular structures in endothelial cells in MPGN are suggestive of lupus nephritis (",
"    <a class=\"graphic graphic_picture graphicRef79072 \" href=\"mobipreview.htm?33/37/34392\">",
"     picture 7",
"    </a>",
"    ), and a fingerprint pattern associated with cryoprecipitates is seen in mixed cryoglobulinemia (",
"    <a class=\"graphic graphic_picture graphicRef81450 \" href=\"mobipreview.htm?35/5/35929\">",
"     picture 8",
"    </a>",
"    ) or rarely in lupus nephritis associated with cryoglobulinemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43833/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/3/27706?source=see_link&amp;anchor=H7#H7\">",
"     \"Diagnosis and classification of renal disease in systemic lupus erythematosus\", section on 'Classification'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/15/34040?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical manifestations and diagnosis of the mixed cryoglobulinemia syndrome (essential mixed cryoglobulinemia)\", section on 'Renal disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H261825925\">",
"    <span class=\"h3\">",
"     Infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immune complex-mediated MPGN is most commonly secondary to hepatitis C and B viral infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43833/abstract/2,14,22-24\">",
"     2,14,22-24",
"    </a>",
"    ]. The incidence of HCV-associated MPGN varies with location. As examples, HCV appears to be a common cause of MPGN in Japan [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43833/abstract/12\">",
"     12",
"    </a>",
"    ] but is an uncommon cause in France and South Africa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43833/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. HCV-induced MPGN is typically associated with mixed cryoglobulinemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/30/37353?source=see_link&amp;anchor=H3#H3\">",
"     \"Renal disease associated with hepatitis C virus infection\", section on 'Membranoproliferative glomerulonephritis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/28/44488?source=see_link&amp;anchor=H4#H4\">",
"     \"Renal disease associated with hepatitis B virus infection\", section on 'Membranoproliferative glomerulonephritis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/15/34040?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical manifestations and diagnosis of the mixed cryoglobulinemia syndrome (essential mixed cryoglobulinemia)\", section on 'Renal disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to HCV, chronic bacterial (eg, endocarditis, shunt nephritis, abscesses), fungal, and, particularly in the developing world, parasitic infections (eg, schistosomiasis, echinococcosis) can cause MPGN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43833/abstract/12,13,27-29\">",
"     12,13,27-29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/27/5556?source=see_link&amp;anchor=H2#H2\">",
"     \"Renal disease in the setting of infective endocarditis or an infected ventriculoatrial shunt\", section on 'Glomerulonephritis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/28/34243?source=see_link&amp;anchor=H3#H3\">",
"     \"Schistosomiasis and glomerular disease\", section on 'Clinicopathologic manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H455985652\">",
"    <span class=\"h3\">",
"     Autoimmune disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immune complex-mediated MPGN is observed in patients with systemic lupus erythematosus (particularly in the chronic phase of lupus nephritis) and, less often, Sj&ouml;gren's syndrome or rheumatoid arthritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43833/abstract/18,30,31\">",
"     18,30,31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/3/27706?source=see_link&amp;anchor=H11#H11\">",
"     \"Diagnosis and classification of renal disease in systemic lupus erythematosus\", section on 'Diffuse lupus nephritis (class IV)'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/12/20677?source=see_link&amp;anchor=H6#H6\">",
"     \"Renal disease in Sj&ouml;gren's syndrome\", section on 'Glomerular disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H455985660\">",
"    <span class=\"h3\">",
"     Dysproteinemias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dysproteinemias are an important cause of MPGN and can be associated on immunofluorescence microscopy with either monoclonal immunoglobulin deposition, as discussed in this section [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43833/abstract/17,32-39\">",
"     17,32-39",
"    </a>",
"    ], or isolated complement deposition in dense deposit disease (DDD) and C3 glomerulonephritis (C3GN), as discussed below. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Complement-mediated MPGN'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H119004535\">",
"     'Dense deposit disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In a retrospective review of renal biopsies performed at the Mayo Clinic, 28 of 68 patients (41 percent) who had a diagnosis of MPGN and were not infected with either hepatitis B or C virus had a monoclonal gammopathy, as determined by serum",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    urine electrophoresis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43833/abstract/17\">",
"     17",
"    </a>",
"    ]. A diagnosis of monoclonal gammopathy of undetermined significance (MGUS) was made in 16 patients; the 12 remaining patients had lymphoma or multiple myeloma. However, by definition, the diagnosis of MGUS requires that end-organ damage not be present. We prefer the term \"monoclonal gammopathy-associated MPGN\" since the term \"MGUS\" refers to undetermined hematologic significance, not the presence of nonhematologic manifestations. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/59/15290?source=see_link&amp;anchor=H90176110#H90176110\">",
"     \"Diagnosis of monoclonal gammopathy of undetermined significance\", section on 'Diagnostic criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical features and prognosis of MPGN associated with monoclonal gammopathy were described in a study of 37 patients who had monoclonal IgG deposits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43833/abstract/37\">",
"     37",
"    </a>",
"    ]. Nephrotic syndrome, renal insufficiency, and hematuria were present in 49, 68, and 77 percent, respectively. Of 32 patients who were followed for over two years, 22 percent progressed to end-stage renal disease (ESRD), 38 percent had complete or partial recovery, and 38 percent had persistent renal dysfunction. Only one patient had multiple myeloma.",
"   </p>",
"   <p>",
"    Cases of MPGN in patients with chronic lymphocytic leukemia have also been described, usually in association with mixed cryoglobulinemia or noncryoprecipitating monoclonal IgG or IgM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43833/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/6/24680?source=see_link&amp;anchor=H11#H11\">",
"     \"Epidemiology and clinical manifestations of chronic lymphocytic leukemia\", section on 'Membranoproliferative glomerulonephritis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Recurrence of MPGN with monoclonal IgG deposits has been described in transplanted kidneys [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43833/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/54/32614?source=see_link&amp;anchor=H2#H2\">",
"     \"Membranoproliferative glomerulonephritis: Recurrence after transplantation\", section on 'MPGN type I'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H274990906\">",
"    <span class=\"h3\">",
"     Rare causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rare causes of MPGN include non-Hodgkin lymphoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43833/abstract/42\">",
"     42",
"    </a>",
"    ], renal cell carcinoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43833/abstract/43\">",
"     43",
"    </a>",
"    ], snake venom [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43833/abstract/44\">",
"     44",
"    </a>",
"    ], splenorenal shunt surgery for portal hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43833/abstract/45\">",
"     45",
"    </a>",
"    ], melanoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43833/abstract/46\">",
"     46",
"    </a>",
"    ], and alpha-1-antitrypsin deficiency. Idiopathic MPGN is a diagnosis of exclusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43833/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/45/18136?source=see_link&amp;anchor=H11#H11\">",
"     \"Extrapulmonary manifestations of alpha-1 antitrypsin deficiency\", section on 'Glomerulonephritis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Complement-mediated MPGN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complement-mediated MPGN is less common than immune complex-mediated MPGN and results from dysregulation and persistent activation of the alternative complement pathway [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43833/abstract/8,9,29,30\">",
"     8,9,29,30",
"    </a>",
"    ]. This form of MPGN is due to the deposition of complement products along the capillary walls and in the mesangium. Immunofluorescence microscopy of kidney sections demonstrates bright C3 staining (",
"    <a class=\"graphic graphic_picture graphicRef76040 \" href=\"mobipreview.htm?22/12/22727\">",
"     picture 9",
"    </a>",
"    ), but no immunoglobulin staining, in the mesangium and along the capillary walls.",
"   </p>",
"   <p>",
"    Complement-mediated MPGN may be further classified based upon ultrastructural features observed on EM as DDD or C3GN. Some genetic mutations that have been associated with these disorders are also associated with atypical hemolytic uremic syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43833/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/52/43849?source=see_link&amp;anchor=H8#H8\">",
"     \"Atypical hemolytic uremic syndrome in children\", section on 'Complement dysregulation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As mentioned above, hypocomplementemia is a characteristic finding in most patients with MPGN. However, a normal C3 concentration does not exclude complement-mediated MPGN, and it is not unusual to find a normal C3 concentration in the chronic phases of the disease, as in adults with DDD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43833/abstract/6\">",
"     6",
"    </a>",
"    ] or patients with C3GN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43833/abstract/49\">",
"     49",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1217072877\">",
"     'Introduction and clinical presentation'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H119004535\">",
"    <span class=\"h3\">",
"     Dense deposit disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dense deposit disease (DDD, also called MPGN type II) is a rare form of MPGN that affects both children and young adults. It has also been associated with monoclonal gammopathies in older adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43833/abstract/50\">",
"     50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/26/3498?source=see_link&amp;anchor=H4#H4\">",
"     \"Dense deposit disease (membranoproliferative glomerulonephritis type II)\", section on 'Case studies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On light microscopy, patterns of injury other than MPGN can also be seen, including mesangial proliferative, diffuse proliferative, crescentic glomerulonephritis, and a sclerosing glomerulopathy. Immunofluorescence microscopy demonstrates C3 deposits, and EM (required to establish the diagnosis) shows the characteristic sausage-shaped, wavy, densely osmophilic deposits along the glomerular basement membranes (GBM) and mesangium (from which the disease receives its name) (",
"    <a class=\"graphic graphic_picture graphicRef73319 \" href=\"mobipreview.htm?24/19/24883\">",
"     picture 10",
"    </a>",
"    ). A finding that may be present in DDD that is not seen in other forms of MPGN is drusen on fundoscopic examination. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/26/3498?source=see_link\">",
"     \"Dense deposit disease (membranoproliferative glomerulonephritis type II)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H455985668\">",
"    <span class=\"h3\">",
"     C3 glomerulonephritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;C3 glomerulonephritis (C3GN, also called glomerulonephritis with isolated C3 deposits) is, like DDD, caused by excessive activation of the alternative complement cascade due (in most patients) to mutations in or antibodies to complement regulating proteins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43833/abstract/8,48,49,51-53\">",
"     8,48,49,51-53",
"    </a>",
"    ]. C3GN has also been reported in association with monoclonal gammopathies and anti-factor H activity, as well as with inherited disease due to mutations in the CFHR5 gene (CFHR5 nephropathy) and a mutation producing a CFHR1-CFHR3 hybrid gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43833/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H37578836\">",
"     'CFHR5 nephropathy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Light microscopy often shows an MPGN pattern of injury, although other forms of glomerulonephritis may be seen, including mesangial proliferative, diffuse proliferative, crescentic glomerulonephritis, and a sclerosing glomerulopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43833/abstract/48,51,56-58\">",
"     48,51,56-58",
"    </a>",
"    ]. Immunofluorescence microscopy shows extensive C3 deposition along the capillary walls and mesangium (",
"    <a class=\"graphic graphic_picture graphicRef76040 \" href=\"mobipreview.htm?22/12/22727\">",
"     picture 9",
"    </a>",
"    ) with",
"    <strong>",
"     no",
"    </strong>",
"    significant immunoglobulin deposition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43833/abstract/8,48,51,59\">",
"     8,48,51,59",
"    </a>",
"    ]. EM demonstrates deposits that are similar to those seen with immune complex-mediated MPGN but does not show the typical sausage-shaped intramembranous and mesangial deposits observed in DDD (",
"    <a class=\"graphic graphic_picture graphicRef50927 \" href=\"mobipreview.htm?10/17/10522\">",
"     picture 11",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Patients with C3GN typically present with proteinuria, which can be associated with nephrotic syndrome, hematuria, and variable degrees of hypertension and azotemia. C3 levels are usually low, C4 levels are normal, and some patients have a C3 convertase-stabilizing autoantibody called C3 nephritic factor (or C3NeF), which is also seen in DDD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43833/abstract/48,51,52\">",
"     48,51,52",
"    </a>",
"    ]. A normal C3 does not exclude C3GN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43833/abstract/49,60\">",
"     49,60",
"    </a>",
"    ]. There may be progression to ESRD, and C3GN can recur after renal transplantation.",
"   </p>",
"   <p>",
"    Some patients develop hematuria after an upper respiratory infection (URI). In a report of nine patients who presented with hematuria following a nonstreptococcal URI and had glomerulonephritis on renal biopsy, six had mesangial C3 deposits, and four had hypocomplementemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43833/abstract/61\">",
"     61",
"    </a>",
"    ]. These findings suggest that the patients may have had a form of C3GN that had not been described at the time of publication. In addition, hematuria after a URI is well described in CFHR5 nephropathy, as described in the next section.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37578836\">",
"    <span class=\"h4\">",
"     CFHR5 nephropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A familial form of C3GN has been described in patients of Cypriot origin due to a mutation in the gene for complement factor H-related protein 5 (CFHR5) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43833/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. In a cohort of 84 Cypriots with unexplained renal disease, four (5 percent) had CFHR5 nephropathy, as detected by mutation analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43833/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CFHR5 nephropathy has the following genetic features [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43833/abstract/64\">",
"     64",
"    </a>",
"    ]. Inheritance is autosomal dominant with more than 90 percent penetrance. The mutation involves a genomic duplication in the CFHR5 gene that results in an elongated version of the CFHR5 protein. The mutation is present in about 1 in 6500 Cypriots and is associated with an extended haplotype flanking the mutation, pointing toward a common ancestor.",
"   </p>",
"   <p>",
"    The clinical manifestations include hematuria in approximately 90 percent, accompanied by proteinuria in 38 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43833/abstract/63\">",
"     63",
"    </a>",
"    ]. Episodes of macroscopic (gross) hematuria can occur within one to two days of a URI and can be recurrent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43833/abstract/62\">",
"     62",
"    </a>",
"    ]. The serum C3 concentrations at presentation have been poorly characterized among patients with CFHR5 nephropathy. Among CHFR5 mutation carriers over age 50, men are much more likely than women to develop chronic kidney disease (80 versus 21 percent) and ESRD (78 versus 4 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43833/abstract/63\">",
"     63",
"    </a>",
"    ]. The development of proteinuria (greater than 1 to 1.5",
"    <span class=\"nowrap\">",
"     g/day)",
"    </span>",
"    is a major predictor of a progressive disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43833/abstract/63\">",
"     63",
"    </a>",
"    ]. Recurrent nephropathy can occur in transplanted kidneys [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43833/abstract/65\">",
"     65",
"    </a>",
"    ]. There is no treatment of proven efficacy. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1217075066\">",
"    <span class=\"h4\">",
"     Distinction from postinfectious glomerulonephritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with MPGN have subepithelial and subendothelial deposits on EM (ie, MPGN type III as described below) and are complement positive but immunoglobulin negative by immunofluorescence microscopy. Some of these cases have been attributed to resolving postinfectious glomerulonephritis because of the presence of subepithelial deposits on EM, even in the absence of a history of recent infection. In such cases, bright C3 staining and lack of significant immunoglobulin staining raise the possibility of C3GN. Consistent with this hypothesis, abnormalities in the alternative complement pathway have been found in many of these patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43833/abstract/49,66-68\">",
"     49,66-68",
"    </a>",
"    ]. In contrast, postinfectious glomerulonephritis is associated with both bright C3 staining and IgG deposition (",
"    <a class=\"graphic graphic_picture graphicRef56846 \" href=\"mobipreview.htm?7/1/7184\">",
"     picture 12",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Findings on EM may also help to distinguish C3GN from postinfectious glomerulonephritis. C3GN is usually associated with abundant large mesangial, subendothelial, and occasionally subepithelial or intramembranous deposits that have a fuzzy amorphous lobular quality (",
"    <a class=\"graphic graphic_picture graphicRef50927 \" href=\"mobipreview.htm?10/17/10522\">",
"     picture 11",
"    </a>",
"    ). This is in contrast to the well-demarcated subepithelial humps seen in postinfectious glomerulonephritis (",
"    <a class=\"graphic graphic_picture graphicRef76739 \" href=\"mobipreview.htm?38/23/39288\">",
"     picture 13",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/30/35304?source=see_link&amp;anchor=H5#H5\">",
"     \"Poststreptococcal glomerulonephritis in children\", section on 'Pathology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H455985677\">",
"    <span class=\"h2\">",
"     MPGN without immunoglobulin or complement deposition",
"    </span>",
"    &nbsp;&mdash;&nbsp;A histologic pattern that may resemble MPGN on light microscopy can be seen in the healing phase of thrombotic microangiopathies (eg, thrombotic thrombocytopenia purpura-hemolytic uremic syndrome), antiphospholipid antibody syndrome, nephropathy associated with bone marrow transplantation, chronic renal allograft nephropathy, radiation nephritis, and malignant hypertension. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/1/29721?source=see_link&amp;anchor=H6#H6\">",
"     \"Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\", section on 'Renal disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35287?source=see_link&amp;anchor=H2#H2\">",
"     \"Antiphospholipid syndrome and the kidney\", section on 'Renal manifestations of APS'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/36/1609?source=see_link&amp;anchor=H9#H9\">",
"     \"Kidney disease following hematopoietic cell transplantation\", section on 'Thrombotic microangiopathy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/61/34778?source=see_link&amp;anchor=H3#H3\">",
"     \"Chronic renal allograft nephropathy\", section on 'Pathology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The common underlying cause of the MPGN pattern in such patients is endothelial injury followed by reparative changes. Immunofluorescence microscopy does not show significant immunoglobulin or complement deposition in the glomeruli, and EM does not show electron dense deposits along the capillary walls.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H559999613\">",
"    <span class=\"h1\">",
"     CLASSIFICATION BASED UPON ELECTRON MICROSCOPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Membranoproliferative glomerulonephritis (MPGN) was initially classified into types I, II, and III based upon electron microscopy (EM). However, this classification has important limitations, and we prefer the classification based upon immunofluorescence microscopy. (See",
"    <a class=\"local\" href=\"#H92986221\">",
"     'Limitations of this classification'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H92986245\">",
"    <span class=\"h2\">",
"     MPGN type I",
"    </span>",
"    &nbsp;&mdash;&nbsp;MPGN type I is characterized by discrete immune deposits in the mesangium and subendothelial space, similar to that seen in lupus nephritis, that are thought to reflect the deposition of circulating immune complexes (",
"    <a class=\"graphic graphic_picture graphicRef64411 \" href=\"mobipreview.htm?8/37/8793\">",
"     picture 5",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H92986252\">",
"    <span class=\"h2\">",
"     MPGN type II",
"    </span>",
"    &nbsp;&mdash;&nbsp;MPGN type II (dense deposit disease, or DDD) is characterized by continuous, dense ribbon-like deposits along the basement membranes of the glomeruli, tubules, and Bowman's capsule (",
"    <a class=\"graphic graphic_picture graphicRef73319 \" href=\"mobipreview.htm?24/19/24883\">",
"     picture 10",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43833/abstract/3,69,70\">",
"     3,69,70",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/26/3498?source=see_link\">",
"     \"Dense deposit disease (membranoproliferative glomerulonephritis type II)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H92986267\">",
"    <span class=\"h2\">",
"     MPGN type III",
"    </span>",
"    &nbsp;&mdash;&nbsp;MPGN type III is similar to MPGN type I except that subepithelial deposits are noted as well as subendothelial deposits. Based upon the EM findings, MPGN type III is further classified into two principal variants, the Strife and Anders variant and the Burkholder variant, which have different patterns of electron dense deposits and disorganization of the glomerular basement membrane (GBM) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/51/43833/abstract/5,71-73\">",
"     5,71-73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many cases of MPGN type III that are immunoglobulin negative but complement positive by immunofluorescence microscopy have been attributed to resolving postinfectious glomerulonephritis because of the presence of subepithelial humps on EM, despite the absence of a history of recent infection. In such cases, bright C3 staining and lack of significant immunoglobulin staining raise the possibility of C3 glomerulonephritis (C3GN). Consistent with this hypothesis, subsequent evaluation demonstrated abnormalities of the alternative complement pathway in many of these patients. (See",
"    <a class=\"local\" href=\"#H455985668\">",
"     'C3 glomerulonephritis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H92986221\">",
"    <span class=\"h2\">",
"     Limitations of this classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Understanding the limitations of the EM classification requires a brief review of complement activation pathways. There are two main pathways: the classic pathway, which is activated when IgG or IgM antibodies bind to antigens; and the alternative pathway, which does not require the presence of antibodies and can be autoactivated by spontaneous cleavage of C3 to C3b, leading to the formation of C3 convertase (",
"    <a class=\"graphic graphic_figure graphicRef59641 \" href=\"mobipreview.htm?13/7/13439\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/25/10647?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview and clinical assessment of the complement system\", section on 'Pathways and activating conditions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The EM-based classification can result in overlap between types I and III. Both types have been considered to be immune complex-mediated glomerulonephritides because of the presence of immune-type electron dense deposits in the mesangium and subendothelial space. However, the following observations suggest that some cases with EM features of MPGN type I or MPGN type III are mediated by complement, not immune, complexes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some cases of MPGN type I have been associated with strong C3 staining without immunoglobulin staining by immunofluorescence microscopy, consistent with a process mediated by complement rather than immune complexes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/51/43833/abstract/74\">",
"       74",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Complement-mediated MPGN'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The majority of cases of MPGN type III show strong C3 staining without immunoglobulin staining by immunofluorescence microscopy, again consistent with a process mediated by complement rather than immune complexes.",
"     </li>",
"     <li>",
"      Markedly depressed serum C3 levels with normal or only mildly decreased serum C4 and C1q levels have been observed in patients with MPGN type I, suggesting possible activation of the alternative rather than the classical complement pathway activated by immune complexes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/51/43833/abstract/71\">",
"       71",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A C3 convertase-stabilizing antibody (called C3 nephritic factor or C3NeF) is found in approximately 80 percent of patients with DDD and results in activation of the alternative complement pathway that characterizes DDD. However, different C3 nephritic factors have been identified in some patients with MPGN types I and III [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/51/43833/abstract/75,76\">",
"       75,76",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/26/3498?source=see_link&amp;anchor=H2#H2\">",
"       \"Dense deposit disease (membranoproliferative glomerulonephritis type II)\", section on 'Pathogenesis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There is an inherited form of MPGN type III that is linked to chromosome 1q32, the locus for the complement receptor family [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/51/43833/abstract/77,78\">",
"       77,78",
"      </a>",
"      ]. These genes code for a highly homologous group of proteins that regulate C3 convertase activity. Abnormalities in any of these proteins may cause excess circulating C3b, mimicking the action of C3NeF [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/51/43833/abstract/77\">",
"       77",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/38/10854?source=see_link\">",
"       \"Regulators and receptors of the complement system\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H80906099\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with membranoproliferative glomerulonephritis (MPGN) can present with a variety of findings, ranging from microscopic hematuria with or without mild proteinuria to nephrotic syndrome and severe glomerulonephritis with hypertension and a reduced glomerular filtration rate. Hypocomplementemia is a common finding. (See",
"      <a class=\"local\" href=\"#H1217072877\">",
"       'Introduction and clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      MPGN is a pattern of glomerular injury viewed by light microscopy that may be caused by multiple pathogenic processes. MPGN is traditionally classified based upon electron microscopy (EM) findings as MPGN types I, II, and III and as secondary MPGN. An alternative classification system that is based upon the pathogenic process (and often identified by immunofluorescence microscopy) is more valuable for the practicing clinician because it helps direct the correct clinical evaluation and design potential disease-specific treatments. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Pathology and pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The two major pathogenetic processes that underlie MPGN are immune complex-mediated and complement-mediated processes. Immune complex-mediated MPGN is characterized by staining for both immunoglobulin and complement by immunofluorescence microscopy, while complement-mediated MPGN is positive for complement but negative for immunoglobulin staining. Immune complex-mediated disorders are usually viral infection-mediated or associated with monoclonal gammopathy or an autoimmune disease. Complement-mediated MPGN may be further classified based upon EM findings as dense deposit disease (DDD) or C3 glomerulonephritis (C3GN). (See",
"      <a class=\"local\" href=\"#H981933439\">",
"       'Classification based upon immunofluorescence microscopy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Immunofluorescence microscopy that is characteristic of immune complex-mediated MPGN should lead to evaluation for infections, autoimmune diseases, and monoclonal gammopathies. (See",
"      <a class=\"local\" href=\"#H455985606\">",
"       'Immune complex-mediated MPGN'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complement-mediated MPGN is less common than immune complex-mediated MPGN. This type of MPGN results from dysregulation and persistent activation of the alternative complement cascade. Immunofluorescence microscopy that is characteristic of complement-mediated MPGN should provoke a search for congenital or acquired defects in the alternative complement cascade. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Complement-mediated MPGN'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      MPGN without immunoglobulin or complement deposition can be seen in patients with antiphospholipid syndrome, the healing phase of thrombotic thrombocytopenic",
"      <span class=\"nowrap\">",
"       purpura/hemolytic-uremic",
"      </span>",
"      syndrome, scleroderma, and transplant glomerulopathy. (See",
"      <a class=\"local\" href=\"#H455985677\">",
"       'MPGN without immunoglobulin or complement deposition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are a variety of rare causes of MPGN. (See",
"      <a class=\"local\" href=\"#H274990906\">",
"       'Rare causes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43833/abstract/1\">",
"      Sethi S, Fervenza FC. Membranoproliferative glomerulonephritis--a new look at an old entity. N Engl J Med 2012; 366:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43833/abstract/2\">",
"      Rennke HG. Secondary membranoproliferative glomerulonephritis. Kidney Int 1995; 47:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43833/abstract/3\">",
"      Smith RJ, Alexander J, Barlow PN, et al. New approaches to the treatment of dense deposit disease. J Am Soc Nephrol 2007; 18:2447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43833/abstract/4\">",
"      Cameron JS, Turner DR, Heaton J, et al. Idiopathic mesangiocapillary glomerulonephritis. Comparison of types I and II in children and adults and long-term prognosis. Am J Med 1983; 74:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43833/abstract/5\">",
"      Strife CF, Jackson EC, McAdams AJ. Type III membranoproliferative glomerulonephritis: long-term clinical and morphologic evaluation. Clin Nephrol 1984; 21:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43833/abstract/6\">",
"      Nasr SH, Valeri AM, Appel GB, et al. Dense deposit disease: clinicopathologic study of 32 pediatric and adult patients. Clin J Am Soc Nephrol 2009; 4:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43833/abstract/7\">",
"      Sethi S, Nester CM, Smith RJ. Membranoproliferative glomerulonephritis and C3 glomerulopathy: resolving the confusion. Kidney Int 2012; 81:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43833/abstract/8\">",
"      Sethi S, Fervenza FC, Zhang Y, et al. Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement. Clin J Am Soc Nephrol 2011; 6:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43833/abstract/9\">",
"      Sethi S, Fervenza FC. Membranoproliferative glomerulonephritis: pathogenetic heterogeneity and proposal for a new classification. Semin Nephrol 2011; 31:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43833/abstract/10\">",
"      Boseman P, Lewin M, Dillon J, Sethi S. Marfan syndrome, MPGN, and bacterial endocarditis. Am J Kidney Dis 2008; 51:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43833/abstract/11\">",
"      Hulton SA, Risdon RA, Dillon MJ. Mesangiocapillary glomerulonephritis associated with meningococcal meningitis, C3 nephritic factor and persistently low complement C3 and C5. Pediatr Nephrol 1992; 6:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43833/abstract/12\">",
"      Yamabe H, Johnson RJ, Gretch DR, et al. Hepatitis C virus infection and membranoproliferative glomerulonephritis in Japan. J Am Soc Nephrol 1995; 6:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43833/abstract/13\">",
"      Yamabe H, Johnson RJ, Gretch DR, et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection responsive to interferon-alpha. Am J Kidney Dis 1995; 25:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43833/abstract/14\">",
"      Alpers CE, Smith KD. Cryoglobulinemia and renal disease. Curr Opin Nephrol Hypertens 2008; 17:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43833/abstract/15\">",
"      Vella J, Carmody M, Campbell E, et al. Glomerulonephritis after ventriculo-atrial shunt. QJM 1995; 88:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43833/abstract/16\">",
"      Adam FU, Torun D, Bolat F, et al. Acute renal failure due to mesangial proliferative glomerulonephritis in a pregnant woman with primary Sj&ouml;gren's syndrome. Clin Rheumatol 2006; 25:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43833/abstract/17\">",
"      Sethi S, Zand L, Leung N, et al. Membranoproliferative glomerulonephritis secondary to monoclonal gammopathy. Clin J Am Soc Nephrol 2010; 5:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43833/abstract/18\">",
"      Weening JJ, D'Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 2004; 65:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43833/abstract/19\">",
"      Glassock RJ, Bargman JM, Palmer BF, et al. Nephrology Quiz and Questionnaire: 2009. Clin J Am Soc Nephrol 2010; 5:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43833/abstract/20\">",
"      Weening JJ, D'Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004; 15:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43833/abstract/21\">",
"      Su CF, Chen HH, Yeh JC, et al. Ultrastructural 'fingerprint' in cryoprecipitates and glomerular deposits: a clinicopathologic analysis of fingerprint deposits. Nephron 2002; 90:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43833/abstract/22\">",
"      Doutrelepont JM, Adler M, Willems M, et al. Hepatitis C infection and membranoproliferative glomerulonephritis. Lancet 1993; 341:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43833/abstract/23\">",
"      Johnson RJ, Gretch DR, Yamabe H, et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 1993; 328:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43833/abstract/24\">",
"      Smith KD, Alpers CE. Pathogenic mechanisms in membranoproliferative glomerulonephritis. Curr Opin Nephrol Hypertens 2005; 14:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43833/abstract/25\">",
"      Rostoker G, Deforges L, Ben Maadi A, et al. Low prevalence of antibodies to hepatitis C virus among adult patients with idiopathic membranoproliferative type I glomerulonephritis in France. Nephron 1995; 69:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43833/abstract/26\">",
"      Madala ND, Naicker S, Singh B, et al. The pathogenesis of membranoproliferative glomerulonephritis in KwaZulu-Natal, South Africa is unrelated to hepatitis C virus infection. Clin Nephrol 2003; 60:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43833/abstract/27\">",
"      Martinelli R, Noblat AC, Brito E, Rocha H. Schistosoma mansoni-induced mesangiocapillary glomerulonephritis: influence of therapy. Kidney Int 1989; 35:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43833/abstract/28\">",
"      Rodrigues VL, Otoni A, Voieta I, et al. Glomerulonephritis in schistosomiasis mansoni: a time to reappraise. Rev Soc Bras Med Trop 2010; 43:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43833/abstract/29\">",
"      Rinc&oacute;n B, Bernis C, Garcia A, Traver JA. Mesangiocapillary glomerulonephritis associated with hydatid disease. Nephrol Dial Transplant 1993; 8:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43833/abstract/30\">",
"      Goules A, Masouridi S, Tzioufas AG, et al. Clinically significant and biopsy-documented renal involvement in primary Sj&ouml;gren syndrome. Medicine (Baltimore) 2000; 79:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43833/abstract/31\">",
"      Cortez MS, Sturgill BC, Bolton WK. Membranoproliferative glomerulonephritis with primary Sj&ouml;gren's syndrome. Am J Kidney Dis 1995; 25:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43833/abstract/32\">",
"      Salant DJ, Sanchorawala V, D'Agati VD. A case of atypical light chain deposition disease--diagnosis and treatment. Clin J Am Soc Nephrol 2007; 2:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43833/abstract/33\">",
"      Alpers CE, Tu WH, Hopper J Jr, Biava CG. Single light chain subclass (kappa chain) immunoglobulin deposition in glomerulonephritis. Hum Pathol 1985; 16:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43833/abstract/34\">",
"      Chang A, Peutz-Kootstra CJ, Richardson CA, Alpers CE. Expanding the pathologic spectrum of light chain deposition disease: a rare variant with clinical follow-up of 7 years. Mod Pathol 2005; 18:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43833/abstract/35\">",
"      Soares SM, Lager DJ, Leung N, et al. A proliferative glomerulonephritis secondary to a monoclonal IgA. Am J Kidney Dis 2006; 47:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43833/abstract/36\">",
"      Nasr SH, Markowitz GS, Stokes MB, et al. Proliferative glomerulonephritis with monoclonal IgG deposits: a distinct entity mimicking immune-complex glomerulonephritis. Kidney Int 2004; 65:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43833/abstract/37\">",
"      Nasr SH, Satoskar A, Markowitz GS, et al. Proliferative glomerulonephritis with monoclonal IgG deposits. J Am Soc Nephrol 2009; 20:2055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43833/abstract/38\">",
"      Masai R, Wakui H, Komatsuda A, et al. Characteristics of proliferative glomerulo-nephritis with monoclonal IgG deposits associated with membranoproliferative features. Clin Nephrol 2009; 72:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43833/abstract/39\">",
"      Moulin B, Ronco PM, Mougenot B, et al. Glomerulonephritis in chronic lymphocytic leukemia and related B-cell lymphomas. Kidney Int 1992; 42:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43833/abstract/40\">",
"      Barbour SJ, Beaulieu MC, Zalunardo NY, Magil AB. Proliferative glomerulonephritis with monoclonal IgG deposits secondary to chronic lymphocytic leukemia. Report of two cases. Nephrol Dial Transplant 2011; 26:2712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43833/abstract/41\">",
"      Nasr SH, Sethi S, Cornell LD, et al. Proliferative glomerulonephritis with monoclonal IgG deposits recurs in the allograft. Clin J Am Soc Nephrol 2011; 6:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43833/abstract/42\">",
"      Rault R, Holley JL, Banner BF, el-Shahawy M. Glomerulonephritis and non-Hodgkin's lymphoma: a report of two cases and review of the literature. Am J Kidney Dis 1992; 20:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43833/abstract/43\">",
"      Ahmed M, Solangi K, Abbi R, Adler S. Nephrotic syndrome, renal failure, and renal malignancy: an unusual tumor-associated glomerulonephritis. J Am Soc Nephrol 1997; 8:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43833/abstract/44\">",
"      Kanjanabuch T, Sitprija V. Snakebite nephrotoxicity in Asia. Semin Nephrol 2008; 28:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43833/abstract/45\">",
"      Dash SC, Bhuyan UN, Dinda AK, et al. Increased incidence of glomerulonephritis following spleno-renal shunt surgery in non-cirrhotic portal fibrosis. Kidney Int 1997; 52:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43833/abstract/46\">",
"      Olson JL, Philips TM, Lewis MG, Solez K. Malignant melanoma with renal dense deposits containing tumor antigens. Clin Nephrol 1979; 12:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43833/abstract/47\">",
"      Fervenza FC, Sethi S, Glassock RJ. Idiopathic membranoproliferative glomerulonephritis: does it exist? Nephrol Dial Transplant 2012; 27:4288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43833/abstract/48\">",
"      Servais A, Fr&eacute;meaux-Bacchi V, Lequintrec M, et al. Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome. J Med Genet 2007; 44:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43833/abstract/49\">",
"      Sethi S, Fervenza FC, Zhang Y, et al. C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up. Kidney Int 2012; 82:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43833/abstract/50\">",
"      Sethi S, Sukov WR, Zhang Y, et al. Dense deposit disease associated with monoclonal gammopathy of undetermined significance. Am J Kidney Dis 2010; 56:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43833/abstract/51\">",
"      Fakhouri F, Fr&eacute;meaux-Bacchi V, No&euml;l LH, et al. C3 glomerulopathy: a new classification. Nat Rev Nephrol 2010; 6:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43833/abstract/52\">",
"      Habbig S, Mihatsch MJ, Heinen S, et al. C3 deposition glomerulopathy due to a functional factor H defect. Kidney Int 2009; 75:1230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43833/abstract/53\">",
"      Fakhouri F, de Jorge EG, Brune F, et al. Treatment with human complement factor H rapidly reverses renal complement deposition in factor H-deficient mice. Kidney Int 2010; 78:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43833/abstract/54\">",
"      Bridoux F, Desport E, Fr&eacute;meaux-Bacchi V, et al. Glomerulonephritis with isolated C3 deposits and monoclonal gammopathy: a fortuitous association? Clin J Am Soc Nephrol 2011; 6:2165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43833/abstract/55\">",
"      Malik TH, Lavin PJ, Goicoechea de Jorge E, et al. A hybrid CFHR3-1 gene causes familial C3 glomerulopathy. J Am Soc Nephrol 2012; 23:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43833/abstract/56\">",
"      Walker PD. Dense deposit disease: new insights. Curr Opin Nephrol Hypertens 2007; 16:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43833/abstract/57\">",
"      Servais A, No&euml;l LH, Dragon-Durey MA, et al. Heterogeneous pattern of renal disease associated with homozygous factor H deficiency. Hum Pathol 2011; 42:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43833/abstract/58\">",
"      Pickering M, Cook HT. Complement and glomerular disease: new insights. Curr Opin Nephrol Hypertens 2011; 20:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43833/abstract/59\">",
"      D'Agati VD, Bomback AS. C3 glomerulopathy: what's in a name? Kidney Int 2012; 82:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43833/abstract/60\">",
"      Servais A, No&euml;l LH, Roumenina LT, et al. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int 2012; 82:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43833/abstract/61\">",
"      Smith MC, Cooke JH, Zimmerman DM, et al. Asymptomatic glomerulonephritis after nonstreptococcal upper respiratory infections. Ann Intern Med 1979; 91:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43833/abstract/62\">",
"      Gale DP, de Jorge EG, Cook HT, et al. Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. Lancet 2010; 376:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43833/abstract/63\">",
"      Athanasiou Y, Voskarides K, Gale DP, et al. Familial C3 glomerulopathy associated with CFHR5 mutations: clinical characteristics of 91 patients in 16 pedigrees. Clin J Am Soc Nephrol 2011; 6:1436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43833/abstract/64\">",
"      Gale DP, Pickering MC. Regulating complement in the kidney: insights from CFHR5 nephropathy. Dis Model Mech 2011; 4:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43833/abstract/65\">",
"      Vernon KA, Gale DP, de Jorge EG, et al. Recurrence of complement factor H-related protein 5 nephropathy in a renal transplant. Am J Transplant 2011; 11:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43833/abstract/66\">",
"      Fr&eacute;meaux-Bacchi V, Weiss L, Demouchy C, et al. Hypocomplementaemia of poststreptococcal acute glomerulonephritis is associated with C3 nephritic factor (C3NeF) IgG autoantibody activity. Nephrol Dial Transplant 1994; 9:1747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43833/abstract/67\">",
"      Halbwachs L, Leveill&eacute; M, Lesavre P, et al. Nephritic factor of the classical pathway of complement: immunoglobulin G autoantibody directed against the classical pathway C3 convetase enzyme. J Clin Invest 1980; 65:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43833/abstract/68\">",
"      Glovsky MM, Ward PA, Johnson KJ. Complement determinations in human disease. Ann Allergy Asthma Immunol 2004; 93:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43833/abstract/69\">",
"      Appel GB, Cook HT, Hageman G, et al. Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. J Am Soc Nephrol 2005; 16:1392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43833/abstract/70\">",
"      Sethi S, Gamez JD, Vrana JA, et al. Glomeruli of Dense Deposit Disease contain components of the alternative and terminal complement pathway. Kidney Int 2009; 75:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43833/abstract/71\">",
"      Strife CF, McEnery PT, McAdams AJ, West CD. Membranoproliferative glomerulonephritis with disruption of the glomerular basement membrane. Clin Nephrol 1977; 7:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43833/abstract/72\">",
"      Burkholder PM, Marchand A, Krueger RP. Mixed membranous and proliferative glomerulonephritis. A correlative light, immunofluorescence, and electron microscopic study. Lab Invest 1970; 23:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43833/abstract/73\">",
"      Anders D. [Membranoproliferative glomerulonephritis]. Dtsch Med Wochenschr 1977; 102:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43833/abstract/74\">",
"      Levy M, Gubler MC, Sich M, et al. Immunopathology of membranoproliferative glomerulonephritis with subendothelial deposits (Type I MPGN). Clin Immunol Immunopathol 1978; 10:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43833/abstract/75\">",
"      Clardy CW, Forristal J, Strife CF, West CD. A properdin dependent nephritic factor slowly activating C3, C5, and C9 in membranoproliferative glomerulonephritis, types I and III. Clin Immunol Immunopathol 1989; 50:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43833/abstract/76\">",
"      Strife CF, Prada AL, Clardy CW, et al. Autoantibody to complement neoantigens in membranoproliferative glomerulonephritis. J Pediatr 1990; 116:S98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43833/abstract/77\">",
"      Neary JJ, Conlon PJ, Croke D, et al. Linkage of a gene causing familial membranoproliferative glomerulonephritis type III to chromosome 1. J Am Soc Nephrol 2002; 13:2052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/51/43833/abstract/78\">",
"      Neary J, Dorman A, Campbell E, et al. Familial membranoproliferative glomerulonephritis type III. Am J Kidney Dis 2002; 40:E1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3055 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-37B631BF3D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_51_43833=[""].join("\n");
var outline_f42_51_43833=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H80906099\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1217072877\">",
"      INTRODUCTION AND CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      PATHOLOGY AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H981933439\">",
"      CLASSIFICATION BASED UPON IMMUNOFLUORESCENCE MICROSCOPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H455985606\">",
"      Immune complex-mediated MPGN",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H261825925\">",
"      - Infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H455985652\">",
"      - Autoimmune disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H455985660\">",
"      - Dysproteinemias",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H274990906\">",
"      - Rare causes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Complement-mediated MPGN",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H119004535\">",
"      - Dense deposit disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H455985668\">",
"      - C3 glomerulonephritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H37578836\">",
"      CFHR5 nephropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1217075066\">",
"      Distinction from postinfectious glomerulonephritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H455985677\">",
"      MPGN without immunoglobulin or complement deposition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H559999613\">",
"      CLASSIFICATION BASED UPON ELECTRON MICROSCOPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H92986245\">",
"      MPGN type I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H92986252\">",
"      MPGN type II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H92986267\">",
"      MPGN type III",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H92986221\">",
"      Limitations of this classification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H80906099\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3055\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3055|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?37/58/38830\" title=\"algorithm 1\">",
"      Proposed classification of MPGN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3055|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?13/7/13439\" title=\"figure 1\">",
"      Complement pathways 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3055|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?24/0/24591\" title=\"picture 1\">",
"      Phase contrast micrograph showing dysmorphic red cells in urine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?13/47/14079\" title=\"picture 2\">",
"      Scanning electron micrograph showing dysmorphic red cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?34/38/35424\" title=\"picture 3\">",
"      Photomicrograph of urine sediment with a red cell cast",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?10/56/11145\" title=\"picture 4A\">",
"      MPGN Light I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?20/21/20825\" title=\"picture 4B\">",
"      MPGN Light II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?8/37/8793\" title=\"picture 5\">",
"      Type I MPGN EM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?38/39/39543\" title=\"picture 6\">",
"      SLE Membranous EM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?33/37/34392\" title=\"picture 7\">",
"      SLE Tubuloreticular",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?35/5/35929\" title=\"picture 8\">",
"      Fingerprint pattern in mixed cryo EM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?22/12/22727\" title=\"picture 9\">",
"      C3 glomerulonephritis IF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?24/19/24883\" title=\"picture 10\">",
"      Dense deposit disease EM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?10/17/10522\" title=\"picture 11\">",
"      C3 glomerulonephritis EM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?7/1/7184\" title=\"picture 12\">",
"      Postinfectious GN IF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?38/23/39288\" title=\"picture 13\">",
"      Postinfectious GN EM",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35287?source=related_link\">",
"      Antiphospholipid syndrome and the kidney",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/52/43849?source=related_link\">",
"      Atypical hemolytic uremic syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/61/34778?source=related_link\">",
"      Chronic renal allograft nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/15/34040?source=related_link\">",
"      Clinical manifestations and diagnosis of the mixed cryoglobulinemia syndrome (essential mixed cryoglobulinemia)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/26/3498?source=related_link\">",
"      Dense deposit disease (membranoproliferative glomerulonephritis type II)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/3/27706?source=related_link\">",
"      Diagnosis and classification of renal disease in systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/59/15290?source=related_link\">",
"      Diagnosis of monoclonal gammopathy of undetermined significance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/1/29721?source=related_link\">",
"      Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/31/27130?source=related_link\">",
"      Differential diagnosis and evaluation of glomerular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/6/24680?source=related_link\">",
"      Epidemiology and clinical manifestations of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/59/34746?source=related_link\">",
"      Etiology and evaluation of hematuria in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/17/13594?source=related_link\">",
"      Evaluation and treatment of membranoproliferative glomerulonephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/45/18136?source=related_link\">",
"      Extrapulmonary manifestations of alpha-1 antitrypsin deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/36/1609?source=related_link\">",
"      Kidney disease following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/54/32614?source=related_link\">",
"      Membranoproliferative glomerulonephritis: Recurrence after transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/25/10647?source=related_link\">",
"      Overview and clinical assessment of the complement system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/30/35304?source=related_link\">",
"      Poststreptococcal glomerulonephritis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/38/10854?source=related_link\">",
"      Regulators and receptors of the complement system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/28/44488?source=related_link\">",
"      Renal disease associated with hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/30/37353?source=related_link\">",
"      Renal disease associated with hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/12/20677?source=related_link\">",
"      Renal disease in Sj&ouml;gren's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/27/5556?source=related_link\">",
"      Renal disease in the setting of infective endocarditis or an infected ventriculoatrial shunt",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/28/34243?source=related_link\">",
"      Schistosomiasis and glomerular disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_51_43834="Initial trauma management in the severely injured child";
var content_f42_51_43834=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F64241&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F64241&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 626px\">",
"   <div class=\"ttl\">",
"    Initial trauma management in children with severe multiple trauma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 606px; height: 1120px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     pCO2: partial pressure of carbon dioxide; O2: oxygen; GCS: Glasgow coma scale; FAST: focused abdominal sonography for trauma.",
"     <br>",
"      * Clinicians should always perform actions in",
"      <span style=\"color:#ff0000\">",
"       RED",
"      </span>",
"      .",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       Administer 20 mL/kg of warmed normal saline or Ringer's lactate over 10 to 20 minutes.",
"       <br>",
"        &Delta; Signs of herniation include coma, unilateral pupillary dilation with outward eye deviation followed by hemiplegia, hyperventilation, Cheyne-Stokes respirations, and/or decerebrate or decorticate posturing.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_51_43834=[""].join("\n");
var outline_f42_51_43834=null;
var title_f42_51_43835="Protocol for treating through clopidogrel hypersensitivity reactions";
var content_f42_51_43835=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F83462&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F83462&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Management of clopidogrel hypersensitivity without drug interruption",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Initial therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Glucocorticoid taper",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Example: Methylprednisolone taper*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Long-acting nonsedating antihistamine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Example: Fexofenadine 180 mg orally each day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Short-acting antihistamine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Example: Diphenhydramine 25 to 50 mg orally before bed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Secondary therapy (for symptom relapse)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Longer course of glucocorticoids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Example: Prednisone 60 mg initially per day, taper by 10 mg every three days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Leukotriene inhibitor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Example: Montelukast 10 mg orally each day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Referral to allergist",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Protocol used at Thomas Jefferson University Hospital.",
"    <div class=\"footnotes\">",
"     * Dosing of glucocorticoids was left to the discretion of the supervising cardiologist.&nbsp;A commonly used regimen was a 6 day tapering course&nbsp;beginning with 24 mg daily (divided into three doses) with total daily dose decreasing by 4 mg a day (Medrol&reg; Dosepak&trade;).",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Campbell KL, Cohn JR, Fischman DL, et al. Management of clopidogrel hypersensitivity without drug interruption. Am J Cardiol 2011; 107:812. Table used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_51_43835=[""].join("\n");
var outline_f42_51_43835=null;
var title_f42_51_43836="NHLBI pediatric definition of lipid levels";
var content_f42_51_43836=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F68183&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F68183&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Definition of lipid levels in children from the 2011 Expert Panel Integrated Guidelines for Cardiovascular Health and Risk reduction in Children and Adolescents*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Category",
"       </td>",
"       <td class=\"subtitle1\">",
"        Acceptable",
"        <br/>",
"        mg/dL (mmol/L)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Borderline",
"        <br/>",
"        mg/dL (mmol/L)",
"       </td>",
"       <td class=\"subtitle1\">",
"        High",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        TC",
"       </td>",
"       <td>",
"        &lt;170 (4.4)",
"       </td>",
"       <td>",
"        170-199 (4.4-5.2)",
"       </td>",
"       <td>",
"        &ge;200 (5.2)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        LDL-C",
"       </td>",
"       <td>",
"        &lt;110 (2.8)",
"       </td>",
"       <td>",
"        110-129 (2.8-3.3)",
"       </td>",
"       <td>",
"        &ge;130 (3.4)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Non-HDL-C",
"       </td>",
"       <td>",
"        &lt;120 (3.1)",
"       </td>",
"       <td>",
"        120-144 (3.1-3.7)",
"       </td>",
"       <td>",
"        &ge;145 (3.8)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ApoB",
"       </td>",
"       <td>",
"        &lt;90 (2.3)",
"       </td>",
"       <td>",
"        90-109 (2.3-2.8)",
"       </td>",
"       <td>",
"        &ge;110 (2.8)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"4\">",
"        TG",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; 0-9 years",
"       </td>",
"       <td class=\"sublist_other\">",
"        &lt;75 (0.8)",
"       </td>",
"       <td class=\"sublist_other\">",
"        75-99 (0.8-1.1)",
"       </td>",
"       <td class=\"sublist_other\">",
"        &ge;100 (1.1)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; 10-19 years",
"       </td>",
"       <td class=\"sublist_other\">",
"        &lt;90 (1 mmol/L)",
"       </td>",
"       <td class=\"sublist_other\">",
"        90-129 (1-1.5)",
"       </td>",
"       <td class=\"sublist_other\">",
"        &ge;130 (1.5)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle1\">",
"        Category",
"       </td>",
"       <td class=\"subtitle1\">",
"        Acceptable",
"       </td>",
"       <td class=\"subtitle1\">",
"        Borderline",
"       </td>",
"       <td class=\"subtitle1\">",
"        Low",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HDL-C",
"       </td>",
"       <td>",
"        &gt;45 (1.2)",
"       </td>",
"       <td>",
"        40-45 (1-1.2)",
"       </td>",
"       <td>",
"        &lt;40 (1.0)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ApoA-1",
"       </td>",
"       <td>",
"        &gt;120 (3.1)",
"       </td>",
"       <td>",
"        115-120 (3-3.1)",
"       </td>",
"       <td>",
"        &lt;115 (3.0)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Values for plasma lipid and lipoprotein levels are from the National Cholesterol Education Program (NCEP) Expert Panel on Cholesterol Levels in Children. Non-HDL-C values from the Bogalusa Heart Study are equivalent to the NCEP Pediatric Panel cut points for LDL-C. Values for plasma apoB and apoA-1 are from the National Health and Nutrition Examination Survey III.",
"     <br>",
"      &Delta; The threshold points for high and borderline-high values&nbsp;represent approximately the 95th and 75th percentiles, respectively. Low&nbsp;threshold points for HDL-C and apoA-1 represent approximately&nbsp;the 10th percentile.",
"      <br>",
"       <br>",
"        TC: triglycerides, LDL-C: low-density lipoprotein cholesterol, HDL-C: high-density lipoprotein, ApoB: apolipoprotein B, ApoA-1: apolipoprotein A-1",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Daniels SR, Benuck I, Christakis DA, et al. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: Full report, 2011. National Heart Lung and Blood Institute. Available at: file://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_51_43836=[""].join("\n");
var outline_f42_51_43836=null;
var title_f42_51_43837="Kaplan Meier curves in COPD";
var content_f42_51_43837=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F58903&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F58903&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Survival in COPD",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 355px; height: 278px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Kaplan-Meier survival curves for nonhypercapnic patients (type 1), reversible hypercapnics (type 2.1), and chronic hypercapnic patients (type 2.2). Survival among type 2.2 patients was significantly worse (P&lt;0.05) by the Cox-Mantel test) than the other two groups. Percentages refer to proportion of patients who survived 5 years.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Costello, R, Deegan, P, Fitzpatrick, M, McNicholas, WT, Am J Med 1997; 103:239.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_51_43837=[""].join("\n");
var outline_f42_51_43837=null;
var title_f42_51_43838="Size classification of varices";
var content_f42_51_43838=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F61770&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F61770&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Size classification of esophageal varices",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 379px; height: 128px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The size of varices, as illustrated in these endoscopic pictures, can be used to estimate the risk of variceal bleeding. The first panel shows small straight varices (F1), the second panel shows enlarged tortuous varices that occupy less than one-third of the lumen (F2), and the third panel shows large coil-shaped varices that occupy more than one-third of the lumen (F3).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Arun Sanyal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_51_43838=[""].join("\n");
var outline_f42_51_43838=null;
var title_f42_51_43839="Complex thyroid nodule Echo";
var content_f42_51_43839=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F55508&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F55508&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Complex thyroid nodule",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 317px; height: 331px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sonogram of the right lobe of the thyroid gland in the transverse plane that shows a large complex thyroid mass.",
"    <div class=\"footnotes\">",
"     H: region of cystic/hemorrhagic degeneration; L: solid portion of the nodule.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Manfred Blum, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_51_43839=[""].join("\n");
var outline_f42_51_43839=null;
